{"numRecords":"430","DataElementQueryResults":[{"publicId":"2002098","version":"3.1","preferredName":"Southwest Oncology Group Treating Institution Identifier Number","preferredDefinition":"information related identification of the SWOG treating institution.","longName":"SWOG_TRT_INST_ID_NUM","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"D6E39E80-CE00-920F-E040-BB89AD434F3E","latestVersionIndicator":"Yes","beginDate":"2005-02-14","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-03-01","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":"ISO compliant - Lung Change Management 7/07 Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3323641","version":"1","preferredName":"Patient Primary  Resection Date","preferredDefinition":"the date that a patient had primary surgical resection.","longName":"PT_SURGICAL_RESEC_DT_PRIM","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3749665-6D2E-D07D-E040-BB89AD437424","latestVersionIndicator":"Yes","beginDate":"2011-12-06","endDate":null,"createdBy":"SMITHA","dateCreated":"2011-12-06","modifiedBy":"MORENOC","dateModified":"2017-06-05","changeNote":"5/16/13 jc moved to SWOG context. 12/6/122 ** ISO COMPLIANCE ** Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3325663","version":"1","preferredName":"Person Hearing Loss Personal Medical History Ind-2","preferredDefinition":"The yes/no indicator whether a partial or complete loss of hearing in one or both ears as part of the account of all medical events and problems a person has experienced.","longName":"3325662v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B385716F-C04B-3E1D-E040-BB89AD437B23","latestVersionIndicator":"Yes","beginDate":"2011-12-07","endDate":null,"createdBy":"SMITHA","dateCreated":"2011-12-07","modifiedBy":"CHILLIJ","dateModified":"2013-05-23","changeNote":"5/16/13 jc moved to SWOG context. Associated with a retired VD. 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3332410","version":"1","preferredName":"Agent HMG-CoA Reductase Inhibitor Recent Use Ind-2","preferredDefinition":"The yes/no indicator related to a patient's/participant's therapy with any substance that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, near to or not long before the present.","longName":"STATIN_USE_IND_2","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B3B0EA74-437E-232D-E040-BB89AD430F75","latestVersionIndicator":"Yes","beginDate":"2011-12-09","endDate":null,"createdBy":"KEARNSD","dateCreated":"2011-12-09","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context. 7/18/12 dw Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3369450","version":"1","preferredName":"Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia Malignant Neoplasm Diagnosis Stratification Code","preferredDefinition":"the coded stratification, a process of classifying patients into strata as part of the randomization process or for purposes of data analysis, by the diagnosis of myelodysplastic syndrome, a clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines or chronic myelomonocytic leukemia, a myelodysplastic/myeloproliferative disease which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20% blasts in the bone marrow or blood, and myelodysplasia.","longName":"3369426v1.0:3369449v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7EF2A14-BEE4-D9A1-E040-BB89AD435F52","latestVersionIndicator":"Yes","beginDate":"2012-02-01","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-01","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3370383","version":"1","preferredName":"Person Malignant Neoplasm Research Diagnostic Imaging Consent Ind-2","preferredDefinition":"the yes/no indicator whether there was consent or permission from a person to use a portion of blood, tissue, or other substance from the body in cancer research, the systematic investigation of the nature of diseases in which abnormal cells divide without control using any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","longName":"3370380v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B814E014-E4C7-37CE-E040-BB89AD434718","latestVersionIndicator":"Yes","beginDate":"2012-02-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-03","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/8/12 Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3370388","version":"1","preferredName":"Patient Other Disease or Disorder Clinical Study Diagnostic Imaging Consent Ind-2","preferredDefinition":"the yes/no indicator whether a patient has consented to allow any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation as part of research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects for other diseases or disorders.","longName":"3370387v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8153C39-2EAF-1D86-E040-BB89AD434FAD","latestVersionIndicator":"Yes","beginDate":"2012-02-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-03","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc  7/11/12 Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3370392","version":"1","preferredName":"Patient Future Communication Diagnostic Imaging Consent Ind-2","preferredDefinition":"the yes/no indicator whether a patient has consented to allow future communication or contact regarding any method that uses a visual display of structural or functional patterns of organs or tissues for diagnostic evaluation.","longName":"3370391v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8155406-F950-F579-E040-BB89AD4359AC","latestVersionIndicator":"Yes","beginDate":"2012-02-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-03","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3376345","version":"1","preferredName":"Diagnostic Procedure Colonoscopy Description Value","preferredDefinition":"Methods, procedures, and tests performed to diagnose disease, disordered function, or disability._Endoscopic examination of the luminal surface of the colon._Description; a statement that represents something in words._A numerical quantity measured or assigned or computed.","longName":"3376343v1.0:3376344v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B88D3D10-F037-DB3D-E040-BB89AD431371","latestVersionIndicator":"Yes","beginDate":"2012-02-09","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-09","modifiedBy":"CHILLIJ","dateModified":"2013-05-23","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3377937","version":"1","preferredName":"Medication Calcium Use Value","preferredDefinition":"The amount of calcium taken that treats or prevents or alleviates the symptoms of disease.","longName":"3377859v1.0:3377929v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8F305E3-F207-DB69-E040-BB89AD4338CC","latestVersionIndicator":"Yes","beginDate":"2012-02-14","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-14","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3378891","version":"1","preferredName":"Dietary Supplement Multivitamin Use Frequency","preferredDefinition":"The number of occurrences of a Multivitamin supplement used within a given time period.","longName":"3378858v1.0:3378861v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-40DF-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3378989","version":"1","preferredName":"Dietary Supplement Single Vitamin Use Frequency","preferredDefinition":"The number of occurrences of a single dietary supplement exclusive of any other vitamin that may not be readily available in the diet.","longName":"3378894v1.0:3378861v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9097AAF-6F98-AA27-E040-BB89AD4357DB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3378990","version":"1","preferredName":"Dietary Supplement Other Use Frequency","preferredDefinition":"The number of occurrences of an other dietary supplement not listed and exclusive of any other vitamin that may not be readily available in the diet.","longName":"3378956v1.0:3378861v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9097AAF-6FBD-AA27-E040-BB89AD4357DB","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379268","version":"1","preferredName":"Medication Ibuprofen Use Frequency","preferredDefinition":"The number of occurrences of using a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic effects (Ibuprofen).","longName":"3379222v1.0:3379213v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91AC57E-1E42-187B-E040-BB89AD4329C2","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-16","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379347","version":"1","preferredName":"Medication Naproxen Use Frequency","preferredDefinition":"The number of occurrences of using a propionic acid derivative and a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, antipyretic and analgesic activities (Naproxen).","longName":"3379225v1.0:3379213v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-CA13-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-16","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379348","version":"1","preferredName":"Medication COX-2 Inhibitor Use Frequency","preferredDefinition":"The number of occurrences of using a subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.","longName":"3379228v1.0:3379213v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-CA4E-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-16","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379349","version":"1","preferredName":"Medication Other Use Frequency","preferredDefinition":"The number of occurrences of using a different than usual non-steroidal anti-inflammatory drugs (NSAID).","longName":"3379230v1.0:3379213v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91D42F1-2717-67E6-E040-BB89AD433700","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-16","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3379356","version":"1","preferredName":"Medication Ibuprofen Use Dose","preferredDefinition":"A quantity of a propionic acid derivate and nonsteroidal anti-inflammatory drug (NSAID) administered, taken, or absorbed at one time.","longName":"3379222v1.0:3379352v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-CB5B-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-16","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380020","version":"1","preferredName":"Surgical Procedure Report Ind-2","preferredDefinition":"A short textual account of a diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue.","longName":"3380019v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9330453-B990-8822-E040-BB89AD4360D2","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-17","modifiedBy":"GARRIDOJ","dateModified":"2016-12-30","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380024","version":"1","preferredName":"Diagnostic Procedure Colonoscope Withdraw Occurrence Ind-2","preferredDefinition":"The yes/no indicator related to the evaluation of the patient and patient's disease using a colonoscope to snip off or cauterize polyps, and to perform biopsies on the colon and rectum.","longName":"3380023v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9337CA7-5708-A6B2-E040-BB89AD437737","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-17","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380029","version":"1","preferredName":"Malignant Neoplasm Colorectal Recurrence Detected Ind-2","preferredDefinition":"the yes/no indicator whether there was detection of the return of signs and/or symptoms of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, that arises in the colon and rectum, or to the entire large bowel.","longName":"3380028v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B933DA41-895A-8C64-E040-BB89AD4308EA","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-17","modifiedBy":"SARAHB","dateModified":"2016-08-10","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380033","version":"1","preferredName":"Malignant Neoplasm Colorectal Second Primary Detected Ind-2","preferredDefinition":"the yes/no indicator whether there was detection of a malignant neoplasm, a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, that arises in the colon and rectum, or to the entire large bowel, as an additional and distinct malignant neoplasm.","longName":"3380032v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B933DA41-897F-8C64-E040-BB89AD4308EA","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-17","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380037","version":"1","preferredName":"Malignant Neoplasm Colon Metastatic Neoplasm Detected Ind-2","preferredDefinition":"the yes/no indicator whether there was detection of a tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues, that arises in the part of the large intestine measured from the cecum to the rectum and has then spread to other parts of the body.","longName":"3380036v1.0:2018320v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9337CA7-57A2-A6B2-E040-BB89AD437737","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-17","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Assessments Ind-2 2018320v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380804","version":"1","preferredName":"Medication Naproxen Use Dose","preferredDefinition":"A quantity of a Naproxen administered, taken, or absorbed at one time.","longName":"3379225v1.0:3379352v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5D9E-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-21","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380805","version":"1","preferredName":"Medication COX-2 Inhibitor Use Dose","preferredDefinition":"A quantity administered, taken, or absorbed of a subgroup of non-steroidal anti-inflammatory drugs (NSAID) that specifically targets at cyclooxygenase 2, an enzyme involved in pain and inflammation.","longName":"3379228v1.0:3379352v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5DC3-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-21","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3380806","version":"1","preferredName":"Medication Other Use Specify","preferredDefinition":"The specified free-text field related to amount of non-steroidal anti-inflammatory drugs (NSAID).","longName":"3379230v1.0:2182161v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B981B613-1612-80A3-E040-BB89AD43514B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-02-21","modifiedBy":"MORENOC","dateModified":"2017-06-16","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3386252","version":"1","preferredName":"Aromatase Inhibitor Administered Month Duration","preferredDefinition":"The period of time that any substance that inhibits aromatase is administered.","longName":"3386247v1.0:3386250v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9BFD21A-6414-E342-E040-BB89AD434C57","latestVersionIndicator":"Yes","beginDate":"2012-02-24","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-02-24","modifiedBy":"CHILLIJ","dateModified":"2013-06-09","changeNote":"6/7/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395736","version":"1","preferredName":"Sulindac Pills Total First Distribution Count","preferredDefinition":"the count of total pills initially dispensed. Sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death.","longName":"3395725v1.0:2018392v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA223546-5996-9D8F-E040-BB89AD434EF7","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"CHILLIJ","dateModified":"2013-05-23","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395737","version":"1","preferredName":"Eflornithine Pills Total First Distribution Count","preferredDefinition":"The total number of Eflornithine/placebo pills from the first distribution.","longName":"3395730v1.0:2018392v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA223546-59D6-9D8F-E040-BB89AD434EF7","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395746","version":"1","preferredName":"Pills Remaining Eflornithine Count","preferredDefinition":"Total number of Eflornithine/placebo pills remaining.","longName":"3395745v1.0:2188893v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2B7-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395752","version":"1","preferredName":"Sulindac Pills Remaining Pills Remaining Count","preferredDefinition":"Total number of Sulindac/placebo pills remaining.","longName":"3395748v1.0:2188893v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D2ED-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395757","version":"2","preferredName":"Eflornithine Pills Received Yes No Indicator","preferredDefinition":"Yes or No response on whether the patient recevied Eflornithine/placebo pills.","longName":"3395754v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31048DD1-3A0C-A3AB-E050-BB89AD4318A6","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"5/16/13 jc moved to SWOG context. CDE versioned due to a change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395771","version":"2","preferredName":"Sulindac Pills Received Yes No Indicator","preferredDefinition":"Yes or No response on whether the patient recevied Sulindac/placebo pills.","longName":"3395756v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31048DD1-39B6-A3AB-E050-BB89AD4318A6","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"5/16/13 jc moved to SWOG context. CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395780","version":"1","preferredName":"Eflornithine Pills Follow-up Distribution Pill Dosage Form Number","preferredDefinition":"Total number of Eflornithine/placebo pills dispensed to the patient.","longName":"3395775v1.0:2018762v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D3C2-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395782","version":"1","preferredName":"Sulindac Dispensed Last Visit Pill Dosage Form Number","preferredDefinition":"Total number of Sulindac/placebo pills dispensed to the patient.","longName":"3395778v1.0:2018762v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D3E7-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"SCOTTM","dateModified":"2013-11-07","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3395794","version":"1","preferredName":"Off-Treatment Cancer Prevention Trial Reason","preferredDefinition":"the enumerated list of reasons related to the details of the patient going off protocol treatment on a clinical trial that studies ways of reducing the risk of getting cancer.","longName":"2014024v1.0:3395792v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA228405-D495-608B-E040-BB89AD432912","latestVersionIndicator":"Yes","beginDate":"2012-02-29","endDate":null,"createdBy":"SMITHA","dateCreated":"2012-02-29","modifiedBy":"CHILLIJ","dateModified":"2013-05-23","changeNote":"5/16/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3397490","version":"1","preferredName":"Medication Nonsteroidal Antiinflammatory Drug Use Type","preferredDefinition":"Types of anti-inflammatory agents (non-steroids) taken.","longName":"3397455v1.0:3397489v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA370D1D-F6C1-4BCA-E040-BB89AD430F6C","latestVersionIndicator":"Yes","beginDate":"2012-03-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-01","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3407315","version":"1","preferredName":"Study Site Identifier Name","preferredDefinition":"A facility in which study/protocol activities are conducted.","longName":"STUDY_SITE_NAME","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BA9CF610-C694-1636-E040-BB89AD435372","latestVersionIndicator":"Yes","beginDate":"2012-03-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-03-06","modifiedBy":"LISU","dateModified":"2020-06-12","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3427396","version":"1","preferredName":"Aspirin Regular Use Therapy Ind-3","preferredDefinition":"A yes/no/unknown indicator regarding the routine use of acetylsalicylic acid (aspirin) or products which contain acetylsalicylic acid by a person.","longName":"2443589v1.0:2018278v2.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC684543-701A-9ED8-E040-BB89AD434CEC","latestVersionIndicator":"Yes","beginDate":"2012-03-29","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-03-29","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.  7/9/12 dw Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3431149","version":"1","preferredName":"Malignant Neoplasm Metastatic Colorectal Involvement Diagnosis Specify","preferredDefinition":"The specified free-text field related to the location of a tumor relating to the colon and rectum, or to the entire large bowel, composed of atypical neoplastic, often pleomorphic cells that invades other tissues and extends from its original site of growth to another anatomic site.","longName":"3431146v1.0:3431148v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCBBF54C-EED6-9F9C-E040-BB89AD435479","latestVersionIndicator":"Yes","beginDate":"2012-04-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-04-02","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461159","version":"1","preferredName":"Acetylsalicylic Acid Administered Medication Use Frequency","preferredDefinition":"The number of occurrences of acetylsalicylic acid (aspirin) being administered within a given time period.","longName":"2199727v1.0:3379213v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0149B44-7BB0-FD11-E040-BB89AD4312BB","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461164","version":"1","preferredName":"Acetylsalicylic Acid Administered Medication Use Dose","preferredDefinition":"A quantity of acetylsalicylic acid (aspirin) administered, taken, or absorbed at one time.","longName":"2199727v1.0:3379352v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C016126D-2AAF-B403-E040-BB89AD43229A","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461175","version":"1","preferredName":"Calcium Nutritional Supplement Use Type","preferredDefinition":"Type of supplemental calcium taken.","longName":"2234901v1.0:3461173v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0164BBD-7D67-355F-E040-BB89AD4305FC","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461176","version":"1","preferredName":"Calcium Nutritional Supplement Use Therapies Specify","preferredDefinition":"Specify other supplement(s) taken.","longName":"2234901v1.0:2018810v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0164BBD-7D7D-355F-E040-BB89AD4305FC","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461309","version":"1","preferredName":"Medication Nonsteroidal Antiinflammatory Drug Use Therapies Specify","preferredDefinition":"Specify other anti-inflammatory agents taken.","longName":"3397455v1.0:2018810v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C016E897-E423-65EC-E040-BB89AD432087","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-05-31","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461337","version":"1","preferredName":"Colonoscopy Visit Colonoscopy Reason","preferredDefinition":"Purpose for the colonoscopy.","longName":"CLNPSY_VISIT_RSN","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0175718-4B99-9F70-E040-BB89AD437E7C","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-06-09","changeNote":"6/7/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461343","version":"1","preferredName":"HMG-CoA Reductase Inhibitor Use Therapy Ind-3","preferredDefinition":"Indicator whether the use of compounds that inhibit HMG-CoA reductases shown to directly lower cholesterol synthesis were taken.","longName":"2480492v1.0:2018278v2.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0175718-4C40-9F70-E040-BB89AD437E7C","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-15","modifiedBy":"GARRIDOJ","dateModified":"2016-07-08","changeNote":"5/31/13 jc moved to SWOG context. 7/9/12 dw Replace VD Therapy Ind-3 2018278v2.0 with VD ID#3506034 - Yes No Unknown Indicator  - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461361","version":"1","preferredName":"Largest Colon Polyp Location Code","preferredDefinition":"Code for the location of the largest polyp in the colon.","longName":"LG_CLN_POLP_LCN_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0175718-4D3B-9F70-E040-BB89AD437E7C","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461454","version":"1","preferredName":"Invasive Pancreatic Carcinoma Location Code","preferredDefinition":"The location of a carcinoma in the pancreas.","longName":"2534314v1.0:3461452v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C01C3954-47D3-0F85-E040-BB89AD436134","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-15","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461456","version":"2","preferredName":"Ascites Present Yes No Indicator","preferredDefinition":"A Yes or No response to whether ascites are present, observed, or diagnosed in the patient","longName":"2014498v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103D5C9-DAF4-452B-E050-BB89AD437F66","latestVersionIndicator":"Yes","beginDate":"2012-05-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"REEVESD","dateModified":"2016-10-31","changeNote":"6/7/13 jc moved to SWOG context. CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461559","version":"1","preferredName":"Laboratory Procedure Leukocyte Result Specified Value","preferredDefinition":"information related to the result of a medical procedure that involves testing a sample of blood for leukocytes.","longName":"LAB_RSLT_SP_VAL","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C02C0302-6509-3C59-E040-BB89AD4371BA","latestVersionIndicator":"Yes","beginDate":"2012-05-16","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-16","modifiedBy":"COOPERM","dateModified":"2017-02-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461970","version":"2","preferredName":"Patient Diarrhea Past Week Assessment Yes No Indicator","preferredDefinition":"A Yes or No response as to whether a patient has had a condition of frequent and watery bowel movements in the most recent week, including today.","longName":"3461969v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D309-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2012-05-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"6/24/13 moved to SWOG context. jc CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461975","version":"1","preferredName":"Active Infection Antibiotic Administration Yes No Indicator","preferredDefinition":"Administration of a drug used to treat infections caused by bacteria and other microorganisms, due to an active disorder resulting from the presence and activity of a microbial, viral, or parasitic agent._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3461974v1.0:3461455v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C054BAFB-9247-4E3D-E040-BB89AD435552","latestVersionIndicator":"Yes","beginDate":"2012-05-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-18","modifiedBy":"BMAESKE","dateModified":"2023-09-08","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461979","version":"1","preferredName":"Antibiotic Complete Administration End Date","preferredDefinition":"The date of completion of the act of administration of a drug used to treat infections caused by bacteria and other microorganisms","longName":"3461978v1.0:2188674v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0555D70-DB98-5A35-E040-BB89AD4337F9","latestVersionIndicator":"Yes","beginDate":"2012-05-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-05-18","modifiedBy":"DWARZEL","dateModified":"2013-05-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461985","version":"1.1","preferredName":"Agent Gemcitabine Administration Type","preferredDefinition":"Typr of anticancer drug that belongs to the family of drugs called antimetabolites that was administered.","longName":"3461982v1.0:3461983v1.1","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC97F81E-D0C9-2317-E040-BB89AD4328AB","latestVersionIndicator":"Yes","beginDate":"2014-06-24","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-06-24","modifiedBy":"ROUILLAS","dateModified":"2014-07-25","changeNote":"Version updated to include new permissible values. 6/24/2014 mws","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461990","version":"2","preferredName":"Chemotherapy Prior Folfirinox Regimen Receive Yes No Indicator","preferredDefinition":"Yes or No response to earlier use of the chemicals consisting of fluorouracil, irinotecan hydrochloride, leucovorin calcium and oxaliplatin for the treatment of pancreatic cancer.","longName":"3461989v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D355-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2012-05-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"6/7/13 jc moved to SWOG context. 5/14/13 dw - modified. CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3461994","version":"2","preferredName":"Chemotherapy Prior Fluorouracil/Leucovorin Calcium/Oxaliplatin Receive Yes No Indicator","preferredDefinition":"The Yes or No response to prior use of one of several chemotherapy regimens that include leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin and which may be used in the treatment of advanced-stage and metastatic colorectal cancer.","longName":"3461993v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D2D2-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2012-05-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"MORENOC","dateModified":"2019-04-03","changeNote":"6/7/13 jc moved to SWOG context. CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3462253","version":"2","preferredName":"Positron Emission Tomography Diagnostic Imaging Malignant Neoplasm Assessment Yes No Indicator","preferredDefinition":"Yes or No indicator to a question regarding diagnostic imaging of positron emission tomography (PET), to assess for malignant neoplasms.","longName":"PET_IMAGING","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3104FC5B-D971-25B5-E050-BB89AD433A04","latestVersionIndicator":"Yes","beginDate":"2012-05-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2017-04-27","changeNote":"2/26/14 ms updated VD permissible values; CDE versioned due to change to preferred VD - 4/21/16 dh; Updated Short Name and Definition to be more user-friendly 4/27/17 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3462254","version":"1","preferredName":"Positron Emission Tomography Diagnostic Imaging Malignant Neoplasm Assessment Date","preferredDefinition":"The date of the diagnostic imaging of positron emission tomography (PET), to assess for malignant neoplasms.","longName":"3462243v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C0A7F0D9-7EF6-4F2E-E040-BB89AD433227","latestVersionIndicator":"Yes","beginDate":"2012-05-22","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-05-22","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3462579","version":"2","preferredName":"Therapeutic Procedure Erythropoietin Myeloid Colony Stimulating Factor Receive Yes No Indicator","preferredDefinition":"A yes or no response to whether patient took an administration of Glycoprotein or colony-stimulating factors including granulocyte colony-stimulating factors (also called G-CSF and filgrastim), granulocyte-macrophage colony-stimulating factors (also called GM-CSF and sargramostim), and promegapoietin that stimulate the production of blood cells.","longName":"3462572v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D1FE-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2012-05-23","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"5/31/13 jc moved to SWOG context. CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475056","version":"1","preferredName":"Patient Lifestyle Habit Questionnaire Consent Ind-2","preferredDefinition":"A yes/no question related to a patient's consent to collect data regarding the typical way of life or manner of living of a patient via predetermined sets of questions used to collect data.","longName":"3475035v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1BEC699-428C-9F9F-E040-BB89AD430971","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-05","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/11/12 Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475079","version":"1","preferredName":"Patient Telephone Communication Contact Questionnaire Consent Ind-2","preferredDefinition":"A yes/no question related to a patient's consent to have telephone contact with the patient in regard to predetermined sets of questions used to collect data.","longName":"3475078v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1C1A977-2321-248A-E040-BB89AD4371E4","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-05","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc 7/18/12 Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475082","version":"1","preferredName":"Blood Specimen Pharmacokinetic Study Patient Consent Ind-2","preferredDefinition":"A yes/no question related to permission to use patient's blood for a study of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body.","longName":"3475081v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1C1A977-2364-248A-E040-BB89AD4371E4","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-05","modifiedBy":"CHILLIJ","dateModified":"2013-06-09","changeNote":"6/7/13 jc moved to SWOG context. 11/27/12 dw Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475090","version":"1","preferredName":"Recurrent Disease Risk Stratification Stage","preferredDefinition":"The process of classifying patients into strata as part of the randomization process according to the risk of the return of a disease after a remission.","longName":"3475085v1.0:3475086v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1C33247-EF73-572B-E040-BB89AD4306D1","latestVersionIndicator":"Yes","beginDate":"2012-06-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-05","modifiedBy":"KEARNSD","dateModified":"2015-03-26","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475244","version":"1","preferredName":"Diagnostic Imaging Scan Report Document Upload Comments Text","preferredDefinition":"The free text field for general notes about the transfer of a file containing a short textual account or the data or image obtained by any method used for diagnostic evaluation to a central computer from a smaller computer or a computer at a remote location.","longName":"3475243v1.0:2015802v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D2F445-7E0B-6915-E040-BB89AD431BC9","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-15","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475304","version":"1","preferredName":"Patient Telephone First Attempt Communication Contact Follow-up Date","preferredDefinition":"The date of the first attempt to contact a patient over the telephone.","longName":"3475303v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D56FE3-9CD8-68CB-E040-BB89AD431520","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475308","version":"1","preferredName":"Patient Telephone Second Attempt Communication Contact Follow-up Date","preferredDefinition":"The date of the second attempt to contact a patient over the telephone.","longName":"3475307v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D56FE3-9D25-68CB-E040-BB89AD431520","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475312","version":"1","preferredName":"Patient Telephone Third Attempt Communication Contact Follow-up Date","preferredDefinition":"The date of the third attempt to contact a patient over the telephone.","longName":"3475311v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D56FE3-9D72-68CB-E040-BB89AD431520","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475319","version":"1","preferredName":"Patient Final Communication Contact Certification Letter Follow-up Outcome Type","preferredDefinition":"The result of the final contact with a patient via certified letter.","longName":"3475315v1.0:3475316v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D60C60-7B38-C7C0-E040-BB89AD4330EB","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"FORMBUILDER","dateModified":"2014-07-28","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475327","version":"1","preferredName":"Patient Cancel Withdraw Consent Date","preferredDefinition":"The date of the annulment of the ceasing of a patient's consent.","longName":"3475326v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Standard","id":"C1D60C60-7BCF-C7C0-E040-BB89AD4330EB","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"SOKKERL","dateModified":"2017-03-02","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3475328","version":"1","preferredName":"Document Upload Date","preferredDefinition":"The date of the transfer of a writing that contains information to a central computer from a smaller computer or a computer at a remote location.","longName":"3421436v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1D60C60-7BF4-C7C0-E040-BB89AD4330EB","latestVersionIndicator":"Yes","beginDate":"2012-06-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-06-06","modifiedBy":"TAYLORT","dateModified":"2020-07-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3520406","version":"1","preferredName":"Liver Involved Yes No Indicator","preferredDefinition":"The yes/no indicator of involvement of the liver.","longName":"2014527v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C41C1B2E-3ADF-BB23-E040-BB89AD435F10","latestVersionIndicator":"Yes","beginDate":"2012-07-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-07-05","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3523008","version":"1","preferredName":"Standard Uptake Value Positron Emission Tomography Baseline Assessment Measurement","preferredDefinition":"the measurement of the standard uptake value during a baseline PET assessment.","longName":"3523007v1.0:2231052v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C480F966-55A6-6A8D-E040-BB89AD431B55","latestVersionIndicator":"Yes","beginDate":"2012-07-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-07-10","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3524953","version":"1","preferredName":"Laboratory Procedure Fasting Plasma Glucose Measurement Outcome Date","preferredDefinition":"The date on which information related to the result of the medical procedure that involves testing a sample of blood for fasting glucose, a measurement essential diagnostic modality for different types of carbohydrate metabolism derangements taken following a period of abstaining from food was made.","longName":"2778609v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A6C122-3388-2343-E040-BB89AD435CAA","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"SCOTTM","dateCreated":"2012-07-12","modifiedBy":"SCOTTM","dateModified":"2013-11-06","changeNote":"5/31/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3533379","version":"1","preferredName":"One Year Postoperative Body CT Performed Yes No Indicator","preferredDefinition":"The Yes/No indicator of whether a CT scan was performed one year after operation.","longName":"3533378v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C5232E4B-47C3-25A4-E040-BB89AD430D4F","latestVersionIndicator":"Yes","beginDate":"2012-07-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-07-18","modifiedBy":"CHILLIJ","dateModified":"2013-06-24","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3534482","version":"1","preferredName":"Steroid Therapy Administered End Date","preferredDefinition":"The end date of the administration of steroids as therapy to the patient.","longName":"2014632v1.0:2188674v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C588274B-490F-A47E-E040-BB89AD437713","latestVersionIndicator":"Yes","beginDate":"2012-07-23","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-07-23","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":"2022.9.30 AQT added for ticket request CADSR0001559. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3536760","version":"1","preferredName":"Prior Systemic Therapy Plasma Cell Myeloma Administered Yes No Indicator","preferredDefinition":"the yes/no indicator relating to prior systemic therapy for myeloma","longName":"3536759v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C626321E-6C0A-6B95-E040-BB89AD431ED1","latestVersionIndicator":"Yes","beginDate":"2012-07-31","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-07-31","modifiedBy":"GDEEN","dateModified":"2022-07-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3563300","version":"1","preferredName":"Mitomycin Agent Administered Yes No Indicator","preferredDefinition":"the yes/no indicator related to the administration of an an anticancer drug that belongs to the family of drugs called antitumor antibiotics.","longName":"2859391v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7BB3BF1-B800-1398-E040-BB89AD4334E4","latestVersionIndicator":"Yes","beginDate":"2012-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-20","modifiedBy":"KEARNSD","dateModified":"2014-02-27","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564045","version":"1","preferredName":"Laboratory Procedure Sodium Electrolytes Outcome Electrolytes Sodium Lab Value","preferredDefinition":"a numeric value quantifying the amount of sodium present in peripheral blood serum.","longName":"2189865v1.0:3564044v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CCE2A3-2351-8C43-E040-BB89AD43164F","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"ZHANGWE","dateModified":"2017-09-05","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564058","version":"1","preferredName":"Laboratory Procedure Potassium Electrolytes Outcome Value","preferredDefinition":"a numeric value quantifying the amount of potassium present in peripheral blood serum.","longName":"2189864v1.0:3564057v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CE058C-A61E-77B9-E040-BB89AD435FE6","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564064","version":"1","preferredName":"Surgical Procedure Nephrectomy Performed Yes No Indicator","preferredDefinition":"the yes/no indicator related to the treatment procedure performed to remove all or part of a kidney.","longName":"3564063v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CEC697-B425-812D-E040-BB89AD436CE8","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"MORENOC","dateModified":"2019-08-08","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564065","version":"1","preferredName":"Prior Surgery Performed Yes No Indicator","preferredDefinition":"yes/no indicator related to a prior surgery performed.","longName":"2188752v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CF461E-7F69-8076-E040-BB89AD43619D","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"HARTLEYG","dateModified":"2021-12-22","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564068","version":"1","preferredName":"Prior Hormonal Therapy Administered Yes No Indicator","preferredDefinition":"yes/no indicator related to prior hormonal therapy administered.","longName":"2188728v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CF9003-8EED-BBBC-E040-BB89AD433BC5","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"FORMBUILDER","dateModified":"2015-03-09","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564082","version":"1","preferredName":"Chemotherapy Target Agent Prior Administered Type","preferredDefinition":"information related to the type of prior targeted agent chemotherapy administered","longName":"3564073v1.0:3564079v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7CFF760-26F3-CD7D-E040-BB89AD433C77","latestVersionIndicator":"Yes","beginDate":"2012-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-21","modifiedBy":"DWARZEL","dateModified":"2013-05-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564223","version":"1","preferredName":"Primary Renal Carcinoma Location Renal Carcinoma Anatomic Site","preferredDefinition":"the primary anatomic site/location of renal carcinoma","longName":"3564220v1.0:3564222v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7E1F586-EF41-E2A8-E040-BB89AD432019","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-22","modifiedBy":"DWARZEL","dateModified":"2013-05-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3564245","version":"1","preferredName":"Malignant Neoplasm Regional Lymph Node Metastasis Present Count","preferredDefinition":"The quantity of the existence of cancer that has spread from the lymph node, in which it first appeared, to another organ.","longName":"3564244v1.0:2018392v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7E33F2D-73F4-8473-E040-BB89AD437463","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-22","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3577679","version":"1","preferredName":"Disease or Disorder Cytogenetic Analysis Method Type","preferredDefinition":"Type of technique for analysis of chromosomal and subchromosomal properties and structures, such as those to diagnose, classify, screen for, or manage genetic diseases and abnormalities.","longName":"2861462v1.0:3577678v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C8986F5B-9BAD-1A25-E040-BB89AD4353F1","latestVersionIndicator":"Yes","beginDate":"2012-08-31","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-08-31","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":". Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3613600","version":"1","preferredName":"Disease or Disorder Atypical Ductal Breast Hyperplasia Atypical Lobular Breast Hyperplasia Lobular Breast Carcinoma In Situ Ductal Breast Carcinoma In Situ Invasive Breast Carcinoma Personal Medical History Yes No Indicator","preferredDefinition":"The yes/no indicator related to whether there is a personal history of atypical ductal breast hyperplasia (ADH), atypical lobular breast hyperplasia (ALH), lobular breast carcinoma in situ (LCIS), ductal breast carcinoma in situ (DCIS), or invasive breast cancer.","longName":"3613599v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CBE600E8-6389-DD4B-E040-BB89AD43684D","latestVersionIndicator":"Yes","beginDate":"2012-10-12","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-12","modifiedBy":"MAESKEB","dateModified":"2016-08-25","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3624500","version":"1","preferredName":"Patient Disease Stratification Code","preferredDefinition":"The coded value representing the patient's disease used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"3624498v1.0:3624499v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD6401D7-834C-E6E8-E040-BB89AD4302B1","latestVersionIndicator":"Yes","beginDate":"2012-10-31","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-31","modifiedBy":"KEARNSD","dateModified":"2021-08-03","changeNote":"6/24/13 moved to SWOG context. jc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3624525","version":"1","preferredName":"Clinical Study Prior Therapeutic Procedure Stratification Code","preferredDefinition":"the coded value representing the patient's prior therapy used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"3624521v1.0:3624522v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD6401D7-8446-E6E8-E040-BB89AD4302B1","latestVersionIndicator":"Yes","beginDate":"2012-10-31","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-10-31","modifiedBy":"SOKKERL","dateModified":"2022-03-17","changeNote":"6/7/13 jc moved to SWOG context.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3624621","version":"1","preferredName":"Patient Age Stratification Code","preferredDefinition":"The coded value representing the age range used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"3151720v1.0:3624619v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD75EAAD-FD77-B4FB-E040-BB89AD43194C","latestVersionIndicator":"Yes","beginDate":"2012-11-01","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-11-01","modifiedBy":"SOKKERL","dateModified":"2023-07-07","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3624628","version":"1","preferredName":"Leukemia Malignant Neoplasm Diagnosis Stratification Code","preferredDefinition":"the coded value representing the onset or diagnosis of leukemia used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"3624624v1.0:3624625v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CD75EAAD-FE02-B4FB-E040-BB89AD43194C","latestVersionIndicator":"Yes","beginDate":"2012-11-01","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-11-01","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3630994","version":"1","preferredName":"Clinical Study Protocol Planned Treatment Regimen Stratification Planned Treatment Regimen Stratification Code","preferredDefinition":"information relating to process of classifying patients into strata as part of the randomization process of the action plan for a clinical trial by planned treatment regimen (the intended treatment plan that specifies the dosage, the schedule, and the duration of treatment).","longName":"3630989v1.0:3630990v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF960B59-ED4F-1D41-E040-BB89AD435950","latestVersionIndicator":"Yes","beginDate":"2012-11-28","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-11-28","modifiedBy":"KEARNSD","dateModified":"2015-02-19","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3638822","version":"1","preferredName":"Malignant Neoplasm Cancer Prevention Trial New Recurrence Diagnosis Yes No Indicator","preferredDefinition":"the yes/no indicator related to the diagnosis of a new or recurrent malignant neoplasm within a clinical trial that studies ways of reducing the risk of getting cancer.","longName":"3638821v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D04B52D7-DF4D-5B75-E040-BB89AD4311CB","latestVersionIndicator":"Yes","beginDate":"2012-12-07","endDate":null,"createdBy":"KEARNSD","dateCreated":"2012-12-07","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3653766","version":"1","preferredName":"Clinical Study Protocol Stratum Group Risk Factor Stratification Risk Group Stratification Code","preferredDefinition":"information relating to the process of classifying patients into strata as part of the randomization process of the action plan for a clinical trial by segregating them into groups based on a characteristic that increases the likelihood of a disease, condition or injury, which ultimately is used to assign study subjects to arms on a study._a numbered system for stratification based on risk factors and used for participation on a clinical study.","longName":"3653283v1.0:3653761v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D396C642-2083-4382-E040-BB89AD435E8C","latestVersionIndicator":"Yes","beginDate":"2013-01-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-01-18","modifiedBy":"JOOSTENT","dateModified":"2017-07-26","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3654011","version":"1","preferredName":"Patient Ancillary Study Questionnaire Specimen Consent Yes No Indicator","preferredDefinition":"the yes/no indicator that asks whether the patient has consented to take part in a companion study and provide specimen samples for future analysis.","longName":"3654010v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D3E5E1D1-D007-EE50-E040-BB89AD435A42","latestVersionIndicator":"Yes","beginDate":"2013-01-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-01-22","modifiedBy":"LUY","dateModified":"2013-10-23","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3689262","version":"1","preferredName":"Clinical Study Baseline Pain Stratification Code","preferredDefinition":"the coded value representing the patient's baseline pain score used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"3689256v1.0:3689258v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D62CCA23-8ADE-D069-E040-BB89AD432441","latestVersionIndicator":"Yes","beginDate":"2013-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-02-20","modifiedBy":"PRICEA","dateModified":"2013-10-25","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3700897","version":"1","preferredName":"Clinical Study Protocol Chemotherapy Planned Treatment Regimen Stratification Code","preferredDefinition":"information related to the planned regimen of chemotherapy agents administered to the patient as a stratification point._a numbered system for stratification based on type of chemotherapy and used for participation on a clinical study.","longName":"3700894v1.0:3700895v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D84CC838-0B81-1124-E040-BB89AD437C00","latestVersionIndicator":"Yes","beginDate":"2013-03-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-03-19","modifiedBy":"KEARNSD","dateModified":"2014-09-02","changeNote":"Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3717975","version":"1","preferredName":"Alternative Investigator Name","preferredDefinition":"the name of an individual who is an alternative investigator.","longName":"3717974v1.0:2018284v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D990D791-1C21-D9FC-E040-BB89AD437F02","latestVersionIndicator":"Yes","beginDate":"2013-04-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-04-04","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3717994","version":"1","preferredName":"Alternative Principal Investigator Person E-mail Address Text","preferredDefinition":"the free-text field for the telecommunications location to which electronic mail can be delivered to an alternative primary investigator who is responsible for all aspects of the conduct of a study at an individual institution.","longName":"3717993v1.0:2484074v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D99118FE-7FB9-7520-E040-BB89AD43577D","latestVersionIndicator":"Yes","beginDate":"2013-04-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-04-04","modifiedBy":"ONEDATA","dateModified":"2022-12-28","changeNote":"3/1/22 jk Designated, added RS, CDS alt name and CSI.  ---- Moved content from CTEP to SWOG","administrativeNotes":"11/5/22 updated CDS Alt Name. jk","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3717997","version":"1","preferredName":"Alternative Principal Investigator Person Telephone Number","preferredDefinition":"the telephone number of an alternative principal investigator, the person who is responsible for all aspects of the conduct of a study at a particular institution.","longName":"3717996v1.0:2016227v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D99118FE-7FEF-7520-E040-BB89AD43577D","latestVersionIndicator":"Yes","beginDate":"2013-04-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-04-04","modifiedBy":"SBR","dateModified":"2013-06-28","changeNote":" Moved content from CTEP to SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3774535","version":"1","preferredName":"Prior Immunotherapy Administered Yes No Indicator","preferredDefinition":"Yes or No to whether prior immunotherapy was administered.","longName":"3774272v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE47389B-4DFC-0180-E040-BB89AD4338A4","latestVersionIndicator":"Yes","beginDate":"2013-06-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-06-03","modifiedBy":"ZHWENDY","dateModified":"2023-06-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3775375","version":"1","preferredName":"Prior Treatment Oxaliplatin Irinotecan Received Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether the patient received prior treatment with oxaliplatin or irinotecan.","longName":"3775374v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE6B3ED1-9EF8-50C6-E040-BB89AD436688","latestVersionIndicator":"Yes","beginDate":"2013-06-05","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-06-05","modifiedBy":"SCOTTM","dateModified":"2013-06-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3778542","version":"1","preferredName":"Patient Quality of Life Ancillary Study Questionnaire Specimen Consent Yes No Indicator","preferredDefinition":"the yes/no indicator related to whether the patient has consented to give permission for questions and information concerning Quality of Life and to take part in, and provide research specimens for, a clinical protocol which is secondary to another protocol in which the individual is already enrolled.","longName":"3778541v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DED2B444-EB69-0BBD-E040-BB89AD4360E5","latestVersionIndicator":"Yes","beginDate":"2013-06-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-06-10","modifiedBy":"LUY","dateModified":"2013-10-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3788091","version":"1","preferredName":"Laboratory Procedure TGF-Beta Receptor Type-1 Signal Transduction Neoplastic Cell Assessment Cell Percentage Value","preferredDefinition":"The percentage value related to testing a sample for the laboratory assessment of ALK-5 tumor cell signal transduction.","longName":"3788077v1.0:2181247v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF73DF8D-A0DB-24DF-E040-BB89AD4307BA","latestVersionIndicator":"Yes","beginDate":"2013-06-18","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-06-18","modifiedBy":"SCOTTM","dateModified":"2013-06-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3788092","version":"1","preferredName":"Laboratory Procedure Bone Morphogenetic Protein Receptor Type-1A Signal Transduction Neoplastic Cell Assessment Cell Percentage Value","preferredDefinition":"The percentage value related to testing a sample for the laboratory assessment of ALK-3 tumor cell signal transduction.","longName":"3788081v1.0:2181247v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DF73DF8D-A109-24DF-E040-BB89AD4307BA","latestVersionIndicator":"Yes","beginDate":"2013-06-18","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-06-18","modifiedBy":"SCOTTM","dateModified":"2013-06-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859113","version":"1","preferredName":"Radical Cystectomy Past Three Years Performed Estimate Number","preferredDefinition":"Estimated number of surgeries to remove all of the bladder (the organ that holds urine) as well as nearby tissues and organs, performed in the past 3 years.","longName":"3859095v1.0:3859112v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E454D4E2-62B6-D0E5-E040-BB89AD433E6E","latestVersionIndicator":"Yes","beginDate":"2013-08-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-19","modifiedBy":"KEARNSD","dateModified":"2013-08-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859444","version":"2","preferredName":"Cystectomy Performed Yes No Indicator","preferredDefinition":"Yes/no response to whether information related to the cystectomy procedure performed.","longName":"2014925v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3103B130-D29F-2546-E050-BB89AD43403D","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"CDE versioned due to change to preferred VD - 4/21/16 dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859448","version":"1","preferredName":"Cystectomy Not Performed Date","preferredDefinition":"The date information related to the date cystectomy procedure not performed.","longName":"3859389v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E46470B0-BF0B-0D34-E040-BB89AD437D9D","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-08-20","modifiedBy":"SCOTTM","dateModified":"2013-08-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859449","version":"1","preferredName":"Cystectomy Performed Off Clinical Study Protocol Ind-3","preferredDefinition":"Yes/no/unknown response to information related to whether cystectomy procedure to be performed off study protocol.","longName":"3859393v1.0:2548257v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E463DDC8-88D7-9FFC-E040-BB89AD430347","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-08-20","modifiedBy":"SCOTTM","dateModified":"2013-08-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859491","version":"2","preferredName":"Disease Recurrent Disease Cancer Progression Diagnosis Yes No Indicator","preferredDefinition":"Yes/no response to information related to the diagnosis of the return of signs and symptoms of cancer after a period of improvement or an increase in the size of a tumor or spread of cancer in the body.","longName":"2195593v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"31033A1F-E628-4427-E050-BB89AD434ABF","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-04-21","modifiedBy":"KEARNSD","dateModified":"2016-04-21","changeNote":"CDE versioned due to change to preferred VD - 4/21/16","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3859493","version":"1","preferredName":"Prior Surgery TUR Treatment Date","preferredDefinition":"Date related to prior surgical transurethral resection treatment.","longName":"2190123v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E46545A2-3270-4C00-E040-BB89AD431CE5","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-08-20","modifiedBy":"SCOTTM","dateModified":"2013-08-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860552","version":"1","preferredName":"Mixed Urothelial Cell Carcinoma Assessment Yes No Indicator","preferredDefinition":"The Yes or No response to whether a patient has a malignant tumor arising from different kinds of epithelial cells found in the layer of transitional epithelium in the wall of the bladder, ureter, and renal pelvis, external to the lamina propria.","longName":"3860551v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E467D428-D0B0-8DC4-E040-BB89AD4350D6","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-20","modifiedBy":"KEARNSD","dateModified":"2013-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860555","version":"1","preferredName":"Squamous Cell Carcinoma Assessment Yes No Indicator","preferredDefinition":"The Yes or No indicator of the assessment of whether the patient has a carcinoma arising from squamous epithelial cells.","longName":"3860554v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E468197D-764D-623B-E040-BB89AD4304DC","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-20","modifiedBy":"SOKKERL","dateModified":"2019-02-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860595","version":"1","preferredName":"Adenocarcinoma Assessment Yes No Indicator","preferredDefinition":"The Yes or No response to whether a patient has a common cancer characterized by the presence of malignant glandular cells.","longName":"3860594v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E46856E3-677C-F78A-E040-BB89AD433250","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-20","modifiedBy":"KEARNSD","dateModified":"2013-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860640","version":"1","preferredName":"Micropapillary Carcinoma Assessment Yes No Indicator","preferredDefinition":"The Yes or No Indicator relating to the assessment of a malignant tumor arising from micropapillary epithelial cells.","longName":"3860633v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E469528A-7CA9-269F-E040-BB89AD435850","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-20","modifiedBy":"MORENOC","dateModified":"2017-06-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860660","version":"1","preferredName":"Other Mixed Urothelial Cell Carcinoma Histology Yes No Indicator","preferredDefinition":"A Yes or No indicator regarding the assessment of normal and abnormal morphologic characteristics in a malignant tumor arising from mixed epithelial cells, different than the one(s) previously specified or mentioned.","longName":"3860658v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4697DB6-40C0-DAA4-E040-BB89AD434B4A","latestVersionIndicator":"Yes","beginDate":"2013-08-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-20","modifiedBy":"MORENOC","dateModified":"2018-05-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860948","version":"1","preferredName":"Pure Urothelial Cell Carcinoma Assessment Yes No Indicator","preferredDefinition":"A Yes or No indicator regarding the assessment of a malignant neoplasm arising from the transitional epithelium, found in the bladder.","longName":"3860947v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E478E12D-BC37-003B-E040-BB89AD433AA2","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-21","modifiedBy":"KEARNSD","dateModified":"2013-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3860952","version":"1","preferredName":"Clinical T4b Assessment Yes No Indicator","preferredDefinition":"The Yes or No indicator regarding the assessment of the examination and treatment of patients dependent on direct observation of a primary tumor with direct invasion of adjacent structures.","longName":"3860951v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E478E12D-BCAA-003B-E040-BB89AD433AA2","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-21","modifiedBy":"BERGANTW","dateModified":"2018-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861035","version":"1","preferredName":"Gross Lymphadenopathy Assessment Yes No Indicator","preferredDefinition":"The Yes or No Indicator regarding the assessment of a clinical finding indicating that a lymph node is enlarged and visible to the naked eye.","longName":"3861034v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47A9363-1114-AEC2-E040-BB89AD437D65","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-21","modifiedBy":"KEARNSD","dateModified":"2013-08-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861038","version":"1","preferredName":"Gross Lymphadenopathy Location Specify","preferredDefinition":"The free text field to specify the location of a clinical finding indicating that a lymph node is enlarged and visible to the naked eye.","longName":"3861037v1.0:2226669v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47A9363-1155-AEC2-E040-BB89AD437D65","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-21","modifiedBy":"KEARNSD","dateModified":"2013-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861045","version":"1","preferredName":"Clinical T4b Fixation Invasion Area Anatomic Site Specify","preferredDefinition":"The free text field to specify the location within the body where a primary tumor moves one cell type into an area normally occupied by a different cell type.","longName":"3861041v1.0:2226669v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47C0AB5-EA2F-FFBC-E040-BB89AD43790B","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-21","modifiedBy":"KEARNSD","dateModified":"2013-08-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3861079","version":"1","preferredName":"Lymph Node Dissection Anatomic Site","preferredDefinition":"Anatomic site information related to the separation of tissue in the course of a surgical procedure to examine the rounded masses of lymphatic tissue to identify possible disease or pathology.","longName":"2009572v3.0:3861073v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E47CF53F-4DA7-D183-E040-BB89AD434A05","latestVersionIndicator":"Yes","beginDate":"2013-08-21","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-08-21","modifiedBy":"KEARNSD","dateModified":"2013-08-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3862934","version":"1","preferredName":"Lymph Node Positive Involvement Count","preferredDefinition":"The quantity of disease in the lymph node.","longName":"3862933v1.0:2018392v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E491C03E-9EAD-9048-E040-BB89AD434D88","latestVersionIndicator":"Yes","beginDate":"2013-08-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-08-22","modifiedBy":"LEEW","dateModified":"2018-07-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3913478","version":"1","preferredName":"Person Specimen Malignant Neoplasm Research Consent Indicator","preferredDefinition":"the indicator for information related to the consent or permission from a person to use a portion of blood, tissue, or other substance from the body in cancer research, the systematic investigation of the nature of diseases in which abnormal cells divide without control.","longName":"2200958v1.0:2494558v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7C787D4-6DA6-7FCC-E040-BB89AD432EBA","latestVersionIndicator":"Yes","beginDate":"2013-10-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-10-02","modifiedBy":"KEARNSD","dateModified":"2013-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3913479","version":"1","preferredName":"Patient Other Disease or Disorder Clinical Study Consent Indicator","preferredDefinition":"the indicator for information related to patient consent in regards to other disease study.","longName":"2670693v1.0:2494558v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7C81AD3-EDB4-BF92-E040-BB89AD435C96","latestVersionIndicator":"Yes","beginDate":"2013-10-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-10-02","modifiedBy":"KEARNSD","dateModified":"2013-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3913480","version":"1","preferredName":"Patient Future Communication Consent Indicator","preferredDefinition":"the indicator for information related to patient contact consent.","longName":"2189905v1.0:2494558v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7C787D4-6DE4-7FCC-E040-BB89AD432EBA","latestVersionIndicator":"Yes","beginDate":"2013-10-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-10-02","modifiedBy":"KEARNSD","dateModified":"2013-10-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3916417","version":"1","preferredName":"ERCC1 Gene Protein Expression Stratification Code","preferredDefinition":"The stratification code for the transcription of a gene involved in nucleotide excision repair into a message and the subsequent translation into a functional protein.","longName":"3916413v1.0:3916414v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8564A3D-8E2E-45C6-E040-BB89AD432745","latestVersionIndicator":"Yes","beginDate":"2013-10-09","endDate":null,"createdBy":"KEARNSD","dateCreated":"2013-10-09","modifiedBy":"KEARNSD","dateModified":"2013-10-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3921101","version":"1","preferredName":"Local-Regional Disease or Disorder Present At Registration Yes No Indicator","preferredDefinition":"Yes or No response to whether there is local-regional disease present at the time of patient registration.","longName":"3921100v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E8DF14C6-F683-FCFD-E040-BB89AD435F6E","latestVersionIndicator":"Yes","beginDate":"2013-10-16","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-10-16","modifiedBy":"KEARNSD","dateModified":"2015-07-07","changeNote":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"3971908","version":"1","preferredName":"Patient Visit Registration Type","preferredDefinition":"Type of visit at which the patient was registered.","longName":"3971904v1.0:3971906v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EC9307E1-98F4-6867-E040-BB89AD432794","latestVersionIndicator":"Yes","beginDate":"2013-12-02","endDate":null,"createdBy":"SCOTTM","dateCreated":"2013-12-02","modifiedBy":"SCOTTM","dateModified":"2013-12-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4147919","version":"1","preferredName":"Disease Status Stratification Code","preferredDefinition":"the coded value representing the patient's disease status used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"4147793v1.0:4147916v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F226CFE0-649B-445F-E040-BB89AD435F98","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-11","modifiedBy":"PWEST","dateModified":"2014-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4163754","version":"1","preferredName":"Peripheral Blood Other Culture Method Metaphase Present Number","preferredDefinition":"the number of metaphases present in peripheral blood sample subjected to a culture other than those previously specified.","longName":"4163753v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2CCBB1E-82A5-15C2-E040-BB89AD43089F","latestVersionIndicator":"Yes","beginDate":"2014-02-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-19","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4163771","version":"1","preferredName":"Bone Marrow Other Culture Method Metaphase Present Number","preferredDefinition":"the number of metaphases present in bone marrow sample subjected to a method of culture other than those previously specified.","longName":"4163433v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2CCBB1E-82E9-15C2-E040-BB89AD43089F","latestVersionIndicator":"Yes","beginDate":"2014-02-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-19","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4163942","version":"1","preferredName":"Peripheral Blood Culture Method Text","preferredDefinition":"the free-text field for the culture method used in peripheral blood sample.","longName":"4163923v1.0:2017276v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2CCBB1E-833C-15C2-E040-BB89AD43089F","latestVersionIndicator":"Yes","beginDate":"2014-02-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-19","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4167468","version":"1","preferredName":"Total Metaphase Present Number","preferredDefinition":"the total number of metaphases present in sample.","longName":"4167242v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DBBD18-D5D9-027C-E040-BB89AD436EE1","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4167802","version":"1","preferredName":"Total Abnormal Metaphase Present Number","preferredDefinition":"the total number of abnormal metaphases present in sample.","longName":"4167801v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DBBD18-D627-027C-E040-BB89AD436EE1","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168112","version":"1","preferredName":"Total BCR/ABL1 Fusion Gene Probe Interphase Nuclei Present Number","preferredDefinition":"total number interphase nuclei present in a BCR-ABL probe","longName":"4168110v1.0:4168111v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DCD5C8-4DED-48C9-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168181","version":"1","preferredName":"Total BCR/ABL1 Fusion Gene Probe Abnormal Interphase Present Number","preferredDefinition":"total number of abnormal interphases present in a BCR-ABL probe","longName":"4168177v1.0:4168180v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DCD5C8-50E4-48C9-E040-BB89AD436635","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168548","version":"1","preferredName":"Total BCR/ABL1 Fusion Gene Probe Metaphases Present Number","preferredDefinition":"total number of metaphases present in a BCR-ABL probe.","longName":"4168540v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DDB3A3-0CD8-B6AC-E040-BB89AD43585C","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168555","version":"1","preferredName":"Total BCR/ABL1 Fusion Gene Probe Abnormal Metaphases Present Number","preferredDefinition":"total number of metaphases present in a BCR-ABL probe.","longName":"4168553v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DDEABF-EA7D-71A5-E040-BB89AD43667F","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168560","version":"1","preferredName":"Total MLL Gene Probe Interphase Nuclei Present Number","preferredDefinition":"total number interphase nuclei present in an MLL probe","longName":"4168559v1.0:4168111v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DDEABF-EADC-71A5-E040-BB89AD43667F","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168565","version":"1","preferredName":"Total MLL Gene Probe Abnormal Interphases Present Number","preferredDefinition":"total number of abnormal interphases present in an MLL probe.","longName":"4168563v1.0:4168180v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DE2DF7-17D1-F196-E040-BB89AD430544","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168569","version":"1","preferredName":"Total MLL Gene Probe Metaphases Present Number","preferredDefinition":"total number of metaphases present in an MLL probe.","longName":"4168568v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DE2DF7-1815-F196-E040-BB89AD430544","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4168597","version":"1","preferredName":"Total MLL Gene Probe Abnormal Metaphases Present Number","preferredDefinition":"total number of metaphases present in an MLL probe","longName":"4168586v1.0:2017272v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2DE2DF7-1865-F196-E040-BB89AD430544","latestVersionIndicator":"Yes","beginDate":"2014-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-20","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4174111","version":"1","preferredName":"Person Prior Platinum Compound Chemotherapy Treatment Regimen Receive Count","preferredDefinition":"Total number of prior platinum-based chemotherapy received.","longName":"4173949v1.0:2019310v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F340E526-5F1E-1173-E040-BB89AD4319E8","latestVersionIndicator":"Yes","beginDate":"2014-02-25","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-02-25","modifiedBy":"SCOTTM","dateModified":"2014-03-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182671","version":"1","preferredName":"Eye Intraocular Pressure Result in Millimeter of Mercury Number","preferredDefinition":"Numerical result of the fluid pressure within the eye measured in Millimeter of Mercury (mmHg)","longName":"4182653v1.0:4182654v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36CEF50-E090-B908-E040-BB89AD434445","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-27","modifiedBy":"KEARNSD","dateModified":"2014-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182751","version":"1","preferredName":"Laboratory Procedure CD4 Expressing Cell Count Outcome","preferredDefinition":"The outcome of the procedure to determine the amount of the CD4 expressing cells in a sample.","longName":"4182741v1.0:4182742v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36E3B5B-E1AF-1576-E040-BB89AD4375CF","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-27","modifiedBy":"COLLIED","dateModified":"2022-04-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182775","version":"1","preferredName":"Human Immunodeficiency Virus Viral Load Assay Outcome Value","preferredDefinition":"The numeric result of analysis performed to determine the amount of viral particles (HIV) in a sample of blood plasma.","longName":"4182774v1.0:2649684v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36DCB09-D4BC-B59E-E040-BB89AD436C4A","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-27","modifiedBy":"KEARNSD","dateModified":"2014-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182814","version":"1","preferredName":"Nitrosurea Antineoplastic Antibiotic Agent Administered Yes No Indicator","preferredDefinition":"The Yes/No indicator of whether a nitrosurea, or an antibiotic, or its derivative, that can kill or inhibit the growth of tumor cells, was administered.","longName":"4182813v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36DCB09-D59D-B59E-E040-BB89AD436C4A","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-27","modifiedBy":"KEARNSD","dateModified":"2014-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4182831","version":"1","preferredName":"Nitrosurea Antineoplastic Antibiotic Agent Administered End Date","preferredDefinition":"The end date of the administration of a nitrosurea, or an antibiotic, or its derivative, that can kill or inhibit the growth of tumor cells.","longName":"4182813v1.0:2188674v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F36F49D0-B978-AD98-E040-BB89AD432B7B","latestVersionIndicator":"Yes","beginDate":"2014-02-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-02-27","modifiedBy":"KEARNSD","dateModified":"2014-02-27","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188334","version":"1","preferredName":"Patient Prior Medication Brain Neoplasm Receive Yes No Indicator","preferredDefinition":"Yes/no response regardaring information related to prior drug therapy for metastatic brain tumors received.","longName":"4188333v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BC422F-9FBF-CCC6-E040-BB89AD431F26","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-03","modifiedBy":"SOKKERL","dateModified":"2019-06-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188351","version":"1","preferredName":"Patient Prior Medication Brain Neoplasm Receive Last Date","preferredDefinition":"information related to prior drug therapy for metastatic brain tumors received._the last date of an evaluation, assessment, or treatment.","longName":"4188333v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BC422F-9FE5-CCC6-E040-BB89AD431F26","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-03","modifiedBy":"SCOTTM","dateModified":"2014-03-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188354","version":"1","preferredName":"Lung Asymptomatic Malignant Neoplasm Present Yes No Indicator","preferredDefinition":"information regarding the evaluation of the presence of a tumor, that has not produced any signs or symptoms of disease within the lung(s)._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4188353v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BC422F-A023-CCC6-E040-BB89AD431F26","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-03","modifiedBy":"SCOTTM","dateModified":"2014-03-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188371","version":"1","preferredName":"Immunology Inflammatory And Autoimmune Disease Personal Medical History Yes No Indicator","preferredDefinition":"Yes/no response to prior history of autoimmune and/or inflammatory disease.","longName":"3151151v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BCC920-6A93-3162-E040-BB89AD430540","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-03","modifiedBy":"PATELV","dateModified":"2017-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188372","version":"1","preferredName":"Immunology Inflammatory And Autoimmune Disease Personal Medical History Date","preferredDefinition":"Date of prior history of autoimmune and/or inflammatory disease.","longName":"3151151v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3BCC920-6AB9-3162-E040-BB89AD430540","latestVersionIndicator":"Yes","beginDate":"2014-03-03","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-03","modifiedBy":"SCOTTM","dateModified":"2014-03-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188611","version":"1","preferredName":"Patient Corticosteroid Anticonvulsant Agent Administered Last Date","preferredDefinition":"The administration of corticosteroids or anticonvulsants to the patient._the last date of an evaluation, assessment, or treatment.","longName":"4188607v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CAFF32-EC93-8ECF-E040-BB89AD437BDA","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-04","modifiedBy":"SCOTTM","dateModified":"2014-08-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188617","version":"1","preferredName":"Patient Prior Attenuated Live Virus Vaccine Administered Yes No Indicator","preferredDefinition":"information related to the prior administration of a live vaccines prepared from microorganisms which have undergone physical adaptation (e.g., by radiation or temperature conditioning) or serial passage in laboratory animal hosts or infected tissue/cell cultures, in order to produce avirulent mutant strain._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4188616v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CAFF32-ECC8-8ECF-E040-BB89AD437BDA","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-04","modifiedBy":"TSESU","dateModified":"2023-09-28","changeNote":null,"administrativeNotes":"2/14/23 added AQT for NRG ticket number CADSR0002048 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188622","version":"1","preferredName":"Patient Prior Immunosuppressive Therapy Administered Yes No Indicator","preferredDefinition":"Yes/no response to information relating to prior immunosuppressive therapy (therapy used to decrease the body's immune response, such as drugs given to prevent transplant rejection) received by the patient.","longName":"4188620v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CAFF32-ED25-8ECF-E040-BB89AD437BDA","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-04","modifiedBy":"CLOHNES","dateModified":"2023-02-14","changeNote":null,"administrativeNotes":"2/14/23 added AQT for NRG ticket number CADSR0002048 cjl.","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4188623","version":"1","preferredName":"Patient Prior Immunosuppressive Therapy Administered Last Date","preferredDefinition":"information relating to the last date prior immunosuppressive therapy (therapy used to decrease the body's immune response, such as drugs given to prevent transplant rejection) received by the patient.","longName":"4188620v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3CB7F0D-5D8E-A7F8-E040-BB89AD437D8B","latestVersionIndicator":"Yes","beginDate":"2014-03-04","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-04","modifiedBy":"MORENOC","dateModified":"2019-03-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199711","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication Administration Specify","preferredDefinition":"Free text information provided related to the administration of a medication that either inhibits or induces CYP3A4 (induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), whose activity seems a key predictor of drug responsiveness and toxicity.","longName":"2183335v1.0:2179878v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F760DD-280A-65B8-E040-BB89AD432AFA","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-06","modifiedBy":"SCOTTM","dateModified":"2014-03-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199712","version":"1","preferredName":"Cytochrome P450 3A4 Inhibition Induction Medication Administration Last Date","preferredDefinition":"Last date medication that either inhibits or induces CYP3A4 (induced primarily in liver by glucocorticoids, drugs, pesticides, and carcinogens and encoded by human CYP3A4 Gene (Cytochrome P450 IIIA Subfamily), whose activity seems a key predictor of drug responsiveness and toxicity was adminisitered.","longName":"2183335v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F8006E-1410-FF21-E040-BB89AD4341EE","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-06","modifiedBy":"ZHWENDY","dateModified":"2023-09-01","changeNote":null,"administrativeNotes":"9/1/2023: added AQT per cadsr0002804.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199713","version":"1","preferredName":"QT Interval Medication Administered Yes No Indicator","preferredDefinition":"Yes/no response to information related to QT interval medication being administered.","longName":"4199693v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F760DD-283B-65B8-E040-BB89AD432AFA","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-06","modifiedBy":"BOWSERC","dateModified":"2021-05-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199731","version":"1","preferredName":"QT Interval Medication Administered Specify","preferredDefinition":"Free text to specify information related to QT interval medication being administered.","longName":"4199693v1.0:2179878v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F760DD-286B-65B8-E040-BB89AD432AFA","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-06","modifiedBy":"SCOTTM","dateModified":"2014-03-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199738","version":"1","preferredName":"QT Interval Medication Administered Last Date","preferredDefinition":"information related to the date QT interval medication last administered.","longName":"4199693v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F8006E-1463-FF21-E040-BB89AD4341EE","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-06","modifiedBy":"SCOTTM","dateModified":"2014-03-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4199895","version":"1","preferredName":"Chromosome Banding Analysis Cytogenetics Outcome Basis Yes No Unknown Indicator","preferredDefinition":"The Yes/No indicator of whether the examination and interpretation of the treatment of chromosomes to reveal characteristic patterns of horizontal bands is the basis of a cytogenetic result.","longName":"4199894v1.0:3506034v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F3F9701B-791C-80BE-E040-BB89AD433A32","latestVersionIndicator":"Yes","beginDate":"2014-03-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-06","modifiedBy":"SCOTTM","dateModified":"2014-06-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4207274","version":"1","preferredName":"Other 11q23 MLL Gene Chromosomal Translocation Cytogenetic Abnormality Specify","preferredDefinition":"The free text field to describe an 11q23/MLL translocation other than those previously mentioned.","longName":"4207273v1.0:2556910v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F447658F-A7EA-F295-E040-BB89AD437C58","latestVersionIndicator":"Yes","beginDate":"2014-03-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-10","modifiedBy":"SETRAKIN","dateModified":"2019-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4207294","version":"1","preferredName":"Other T-Cell Receptor Chromosomal Translocation Cytogenetic Abnormality Specify","preferredDefinition":"The free text field describing a T-cell receptor translocation other than those previously specified.","longName":"4207293v1.0:2556910v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F447658F-A834-F295-E040-BB89AD437C58","latestVersionIndicator":"Yes","beginDate":"2014-03-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-10","modifiedBy":"SCOTTM","dateModified":"2014-06-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4208233","version":"1","preferredName":"Adult Health Behavior Smoking Status Type","preferredDefinition":"An indication of a person's current tobacco and nicotine consumption as well as some indication of smoking history.","longName":"3094872v1.0:4208192v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4573EBE-E0AD-ED46-E040-BB89AD434D8B","latestVersionIndicator":"Yes","beginDate":"2014-03-11","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-11","modifiedBy":"FORMBUILDER","dateModified":"2019-02-21","changeNote":"6/20/19 per Devin Hamid, updated with human readable def provided. jk  7/24/18 VD updated with 2 new PVs for DCP re-use. dh","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4208793","version":"1","preferredName":"Smoking Duration Week Count","preferredDefinition":"the field to indicate the average numbers of weeks on which the patient smokes.","longName":"2182164v1.0:3534601v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4592A2B-10A8-2C2C-E040-BB89AD43656C","latestVersionIndicator":"Yes","beginDate":"2014-03-11","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-11","modifiedBy":"SCOTTM","dateModified":"2014-04-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4208797","version":"1","preferredName":"Smoking Duration Month Count","preferredDefinition":"the field to indicate the average numbers of months on which the patient smokes.","longName":"2182164v1.0:2497191v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F458FF32-1BD4-E1C0-E040-BB89AD430459","latestVersionIndicator":"Yes","beginDate":"2014-03-11","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-11","modifiedBy":"SCOTTM","dateModified":"2014-04-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4231466","version":"1","preferredName":"Protocol Laboratory Procedure Lactate Dehydrogenase Stratification LDH Stratification Code","preferredDefinition":"information related to a stratification factor based on the laboratory LDH result._A system of numbered categories for representation of data.","longName":"4231455v1.0:4231465v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4D61664-A790-275D-E040-BB89AD43759E","latestVersionIndicator":"Yes","beginDate":"2014-03-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-17","modifiedBy":"KEARNSD","dateModified":"2014-03-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4255056","version":"1","preferredName":"Patient Smoking Status Stratification Code","preferredDefinition":"The coded value of the classification of patients into a sequence of grades or ranks, based on an indication of a person's current tobacco and nicotine consumption as well as some indication of smoking history, as part of the randomization process or for purposes of data analysis.","longName":"4255053v1.0:4255054v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5A25E1E-731D-4DC4-E040-BB89AD437C91","latestVersionIndicator":"Yes","beginDate":"2014-03-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-03-27","modifiedBy":"KEARNSD","dateModified":"2014-03-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4259216","version":"1","preferredName":"Patient Not Registered Reason","preferredDefinition":"information related to the reason patient not being registered.","longName":"2442992v1.0:4259212v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F5EEE383-E0F0-7BDA-E040-BB89AD431D71","latestVersionIndicator":"Yes","beginDate":"2014-03-31","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-03-31","modifiedBy":"KEARNSD","dateModified":"2015-07-07","changeNote":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261290","version":"1","preferredName":"Patient Not Registered Decision Date","preferredDefinition":"Date a decision was made that a patient would not registered with medical professional or institution with the purpose to receive medical care when necessary.","longName":"4261286v1.0:4261289v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F611F113-036E-9F08-E040-BB89AD4346E9","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-04-02","modifiedBy":"SCOTTM","dateModified":"2014-04-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261292","version":"1","preferredName":"Further Treatment Administered Yes No Indicator","preferredDefinition":"Yes/no response to whether further treatment will be administered.","longName":"2009199v3.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F611F113-040C-9F08-E040-BB89AD4346E9","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-04-02","modifiedBy":"SCOTTM","dateModified":"2014-04-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4261431","version":"1","preferredName":"Person Clinical Study Assignment Category","preferredDefinition":"category of study assignments available for subjects to regsiter on a clinical study, research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects.","longName":"3190339v1.0:4261417v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6135557-CEE8-96C5-E040-BB89AD43249A","latestVersionIndicator":"Yes","beginDate":"2014-04-02","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-04-02","modifiedBy":"SCOTTM","dateModified":"2014-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4264524","version":"1","preferredName":"Disease Progression Therapy Type","preferredDefinition":"Evidence of disease progression on therapy._Types of progression of therapy","longName":"4264432v1.0:4264520v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6770547-A59F-ACD9-E040-BB89AD431F13","latestVersionIndicator":"Yes","beginDate":"2014-04-07","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-04-07","modifiedBy":"SCOTTM","dateModified":"2014-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4267089","version":"1","preferredName":"Assessment Extramedullary Disease Involvement Extent Ind","preferredDefinition":"The indicator for the assessment of the involvement of extramedullary disease.","longName":"4267088v1.0:2018823v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F6CAEB42-71EE-CFA2-E040-BB89AD437185","latestVersionIndicator":"Yes","beginDate":"2014-04-11","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-11","modifiedBy":"SETRAKIN","dateModified":"2020-07-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4271555","version":"1","preferredName":"Assessment Extramedullary Disease Method Type","preferredDefinition":"The type of method used to assess extramedullary disease.","longName":"4271553v1.0:4271554v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F72035CB-6F2C-B99E-E040-BB89AD434E3C","latestVersionIndicator":"Yes","beginDate":"2014-04-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-15","modifiedBy":"LEEW","dateModified":"2021-12-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4271594","version":"1","preferredName":"Lumbar Puncture Date","preferredDefinition":"The date of a diagnostic procedure in which a thin needle called a spinal needle is put into the lower part of the spinal column to collect cerebrospinal fluid or to give drugs.","longName":"4271593v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F721D44E-5D6A-170C-E040-BB89AD430E98","latestVersionIndicator":"Yes","beginDate":"2014-04-15","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-15","modifiedBy":"CHANGP","dateModified":"2016-09-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4273794","version":"1","preferredName":"Prior Therapy Acute Lymphoblastic Leukemia Administered Yes No Indicator","preferredDefinition":"The yes/no indicator for information related to the prior treatment of Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.","longName":"4273793v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7353D91-EF3C-9D8B-E040-BB89AD4328CC","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-16","modifiedBy":"MORENOC","dateModified":"2018-08-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4273796","version":"1","preferredName":"Prior Therapy Acute Lymphoblastic Leukemia Administered Text","preferredDefinition":"The free text field to specify the agent received in the prior treatment of Leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.","longName":"4273793v1.0:4273795v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7353D91-EF75-9D8B-E040-BB89AD4328CC","latestVersionIndicator":"Yes","beginDate":"2014-04-16","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-16","modifiedBy":"KEARNSD","dateModified":"2014-04-16","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4274873","version":"1","preferredName":"Acute Lymphoblastic Leukemia Pathologic Diagnosis Date","preferredDefinition":"Date of the pathologic diagnosis of leukemia with an acute onset, characterized by the presence of lymphoblasts in the bone marrow and the peripheral blood.","longName":"4274872v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F746A2C5-C1C7-F9FC-E040-BB89AD4304AF","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-17","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4274895","version":"1","preferredName":"Confirmation Immunophenotype B-cell Lineage Date","preferredDefinition":"Date of immunophenotype confirmation of B-Cell lineage","longName":"4274894v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7478499-6876-B980-E040-BB89AD43738C","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-17","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4274932","version":"1","preferredName":"Philadelphia Chromosome Assessment Status","preferredDefinition":"Assessment of the status of the Philadelphia Chromosome, a translocation between chromosomes 9 and 22 and the hallmark for chronic myelogenous leukemia (CML).","longName":"4274912v1.0:4274931v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7478499-68D5-B980-E040-BB89AD43738C","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-17","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4274954","version":"1","preferredName":"BCR-ABL Cytogenetics Assessment Status","preferredDefinition":"Status assessment of a fusion protein encoded by the BCR/ABL1 fusion gene.","longName":"4274952v1.0:4274953v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F7491FBE-2D29-26C5-E040-BB89AD436F19","latestVersionIndicator":"Yes","beginDate":"2014-04-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-17","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275377","version":"1","preferredName":"Pericardial Effusion Ascites Pleural Effusion Disease or Disorder Present Indicator","preferredDefinition":"Indicator of whether the presence of fluid collection within the pericardial sac, accumulation of fluid in the peritoneal cavity or increased amounts of fluid within the pleural cavity exists.","longName":"4275373v1.0:4275374v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75A4451-A64E-69B8-E040-BB89AD436B80","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"REEVESD","dateModified":"2016-10-31","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275394","version":"1","preferredName":"Patient Personal Medical History Acquired Immunodeficiency Syndrome Event Yes No Indicator","preferredDefinition":"the yes/no indicator of a patient's history of any AIDS-defining event.","longName":"4275393v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75A4451-A698-69B8-E040-BB89AD436B80","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"FORMBUILDER","dateModified":"2015-03-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275415","version":"1","preferredName":"Combination Antiretroviral Therapy Administered Yes No Indicator","preferredDefinition":"The Yes/No indicator of administration of treatment with a combination of drugs that inhibit the ability of the human immunodeficiency virus (HIV) or other types of retroviruses to multiply in the body.","longName":"4275414v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75B9733-DF18-43EF-E040-BB89AD433825","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275451","version":"1","preferredName":"Zidovudine Stavudine Combination Antiretroviral Therapy Administered Yes No Indicator","preferredDefinition":"The Yes/No indicator of the administration of combination antiretroviral therapy (cART) including Zidovudine and Stavudine.","longName":"4275433v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75B9733-DF61-43EF-E040-BB89AD433825","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275474","version":"1","preferredName":"Neuropathy Previous Fourteen Days Present Yes No Indicator","preferredDefinition":"The Yes/No indicator of the presence of a disorder affecting the cranial nerves or the peripheral nervous system in the past 14 days.","longName":"4275473v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75B9733-DFFC-43EF-E040-BB89AD433825","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"KEARNSD","dateModified":"2014-04-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4275492","version":"1","preferredName":"Neuropathy Highest Grade Value","preferredDefinition":"The value of the highest grade of a disorder affecting the cranial nerves or the peripheral nervous system.","longName":"4275477v1.0:4275491v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F75CE714-51CA-86AE-E040-BB89AD433A84","latestVersionIndicator":"Yes","beginDate":"2014-04-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-18","modifiedBy":"MORENOC","dateModified":"2020-05-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4283593","version":"1","preferredName":"Metastatic Recurrent Squamous Cell Lung Carcinoma Diagnosis Duration Stratification Code","preferredDefinition":"The coded value for the stratification of the period of time during which a patient has been diagnosed with metastatic or recurrent squamous cell lung cancer.","longName":"4283590v1.0:4283591v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8350715-3341-1C5E-E040-BB89AD434DA1","latestVersionIndicator":"Yes","beginDate":"2014-04-29","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-29","modifiedBy":"KEARNSD","dateModified":"2014-07-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4284426","version":"1","preferredName":"PIK3CA Mutation Status Stratification Code","preferredDefinition":"The stratification code for the status of a PIK3CA mutation, an enzyme that catalyzes the conversion of phosphatidylinositol to phosphatidylinositol 3-phosphate.","longName":"4284424v1.0:4284425v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F836C4EE-88D2-842A-E040-BB89AD434ED2","latestVersionIndicator":"Yes","beginDate":"2014-04-29","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-04-29","modifiedBy":"KEARNSD","dateModified":"2014-06-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4287269","version":"1","preferredName":"Prior Therapy Type Name","preferredDefinition":"Name of the type of prior therapy.","longName":"4287266v1.0:4287254v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F85AF15C-3F28-6E57-E040-BB89AD4377D7","latestVersionIndicator":"Yes","beginDate":"2014-05-01","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-05-01","modifiedBy":"KEARNSD","dateModified":"2015-07-07","changeNote":"released as part of the 3Q2015 draft content review - 7/7/15, DKH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4293536","version":"1","preferredName":"Alternative Contact Person E-mail Address Text","preferredDefinition":"The free-text field related to the e-mail address of an alternate contact person.","longName":"4293534v1.0:4293535v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F8C2268A-7E5F-DA5E-E040-BB89AD437053","latestVersionIndicator":"Yes","beginDate":"2014-05-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-06","modifiedBy":"NELSONA","dateModified":"2018-12-21","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4296309","version":"1","preferredName":"Pathology Form Pathologist Signature Date","preferredDefinition":"the date of a pathologist's signature on a pathology form","longName":"4296307v1.0:4296308v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F90242AD-2E01-FED5-E040-BB89AD430686","latestVersionIndicator":"Yes","beginDate":"2014-05-09","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-09","modifiedBy":"SBREXT","dateModified":"2016-09-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4296355","version":"1","preferredName":"Strong CYP3A4 Inhibitor CYP3A5 Induction Medication Administration Yes No Indicator","preferredDefinition":"the yes/no indicator of the administration of a medication that either strongly inhibits CYP3A4 (encoded by human CYP3A4 Gene), whose activity seems a key predictor of drug responsiveness and toxicity, or strongly induces Cytochrome P450 3A5 (encoded by the human CYP3A5 gene), a protein involved in the oxidation of steroids, fatty acids, and xenobiotics.","longName":"4296354v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9188A37-2F6B-D0D6-E040-BB89AD4327AB","latestVersionIndicator":"Yes","beginDate":"2014-05-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-10","modifiedBy":"MORENOC","dateModified":"2016-05-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4296356","version":"1","preferredName":"Strong Cytochrome P450 3A4 Inhibitor Cytochrome P450 3A5 Induction Medication Administration Therapy Administered Specify","preferredDefinition":"the free-text field to specify the administration of a medication that either strongly inhibits CYP3A4 (encoded by human CYP3A4 Gene), whose activity seems a key predictor of drug responsiveness and toxicity, or strongly induces Cytochrome P450 3A5 (encoded by the human CYP3A5 gene), a protein involved in the oxidation of steroids, fatty acids, and xenobiotics.","longName":"4296354v1.0:2179878v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9188A37-2F90-D0D6-E040-BB89AD4327AB","latestVersionIndicator":"Yes","beginDate":"2014-05-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-10","modifiedBy":"KEARNSD","dateModified":"2014-05-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4296357","version":"1","preferredName":"Strong Cytochrome P450 3A4 Inhibitor Cytochrome P450 3A5 Induction Medication Administration Last Date","preferredDefinition":"the last date of the administration of a medication that either strongly inhibits CYP3A4 (encoded by human CYP3A4 Gene), whose activity seems a key predictor of drug responsiveness and toxicity, or strongly induces Cytochrome P450 3A5 (encoded by the human CYP3A5 gene), a protein involved in the oxidation of steroids, fatty acids, and xenobiotics.","longName":"4296354v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9188A37-2FB5-D0D6-E040-BB89AD4327AB","latestVersionIndicator":"Yes","beginDate":"2014-05-10","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-10","modifiedBy":"KEARNSD","dateModified":"2014-05-13","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4308476","version":"1","preferredName":"Other Targeted Therapy Administered Type","preferredDefinition":"The free-text field for an alternate type of targeted therapy administered","longName":"4308473v1.0:4308475v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9558F94-0BA3-3339-E040-BB89AD436174","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-14","modifiedBy":"COOPERM","dateModified":"2017-08-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321935","version":"1","preferredName":"Patient Brain Metastases History Yes No Indicator","preferredDefinition":"the yes/no indicator of a patient's history of brain metastases.","longName":"4321934v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CC5695-3A1F-E964-E040-BB89AD43303C","latestVersionIndicator":"Yes","beginDate":"2014-05-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-19","modifiedBy":"KEARNSD","dateModified":"2014-05-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321939","version":"1","preferredName":"Patient Radiotherapy Surgery Treatment Yes No Indicator","preferredDefinition":"the yes/no indicator relating to whether a patient received treatment by radiation therapy or surgery.","longName":"4321938v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CCAFBB-0CC3-FF83-E040-BB89AD431798","latestVersionIndicator":"Yes","beginDate":"2014-05-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-19","modifiedBy":"KEARNSD","dateModified":"2014-05-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321940","version":"1","preferredName":"Patient Radiotherapy Surgery Treatment Date","preferredDefinition":"the date on which a patient's treatment by radiation therapy or surgery occurred.","longName":"4321938v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CCAFBB-0CE8-FF83-E040-BB89AD431798","latestVersionIndicator":"Yes","beginDate":"2014-05-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-19","modifiedBy":"KEARNSD","dateModified":"2014-05-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321944","version":"1","preferredName":"Patient Stable Disease or Disorder Yes No Indicator","preferredDefinition":"the yes/no indicator relating to the stability of a patient's disease","longName":"4321943v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CCAFBB-0D35-FF83-E040-BB89AD431798","latestVersionIndicator":"Yes","beginDate":"2014-05-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-19","modifiedBy":"KNABLEJ","dateModified":"2017-10-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321948","version":"1","preferredName":"Patient Neurologic Asymptomatic Yes No Indicator","preferredDefinition":"the yes/no indicator relating to a patient having no signs or symptoms of neurologic disease.","longName":"4321947v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CCAFBB-0D7F-FF83-E040-BB89AD431798","latestVersionIndicator":"Yes","beginDate":"2014-05-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-19","modifiedBy":"KEARNSD","dateModified":"2014-05-20","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4321971","version":"1","preferredName":"Laboratory Procedure NRAS wt Allele Outcome Date","preferredDefinition":"the date of the testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for the information related to the testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting for the human NRAS wild-type allele is located in the vicinity of 1p13.2 and is approximately 53 kb in length. This allele, which encodes GTPase NRas protein, may be involved in cellular growth modulation. Mutations in the gene are frequent in juvenile and acute myelomonocytic leukemias.","longName":"4321952v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9CE2716-DCB3-AA71-E040-BB89AD433041","latestVersionIndicator":"Yes","beginDate":"2014-05-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-05-20","modifiedBy":"REEVESD","dateModified":"2015-04-28","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4342851","version":"1","preferredName":"Vision Assessment Date","preferredDefinition":"The date of the determination of the visual capabilities of a person by completion of an ophthalmologic evaluation.","longName":"2236588v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FAE6AA78-FC50-55E7-E040-BB89AD434A6C","latestVersionIndicator":"Yes","beginDate":"2014-06-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-06-02","modifiedBy":"COBARRUBIAK","dateModified":"2019-02-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4360375","version":"1","preferredName":"Laboratory Procedure BRAF Gene Mutation Abnormality Present Outcome Yes No Indicator","preferredDefinition":"The yes/no indicator of a laboratory procedure testing for the presence of a mutation of the BRAF gene, a gene involved in cell organization/biogenesis and the inhibition of apoptosis.","longName":"4360374v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC379488-82C3-F05B-E040-BB89AD432BCB","latestVersionIndicator":"Yes","beginDate":"2014-06-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-06-19","modifiedBy":"WONGW","dateModified":"2015-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4369631","version":"1","preferredName":"Liver Metastasis Present Yes No Indicator","preferredDefinition":"The yes/no indicator of the existence of cancer that has spread from the liver, in which it first appeared, to another organ.","longName":"3479985v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCC30C71-4DF0-FC4C-E040-BB89AD4315C0","latestVersionIndicator":"Yes","beginDate":"2014-06-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-06-26","modifiedBy":"SOKKERL","dateModified":"2023-05-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4370134","version":"1","preferredName":"Primary Neoplasm Description Stratification Code","preferredDefinition":"A description of the primary tumor_A system of numbered categories for representation of stratification data.","longName":"4370132v1.0:4370133v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCDA205E-76E2-85D3-E040-BB89AD4329AA","latestVersionIndicator":"Yes","beginDate":"2014-06-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-06-27","modifiedBy":"KEARNSD","dateModified":"2014-07-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4370282","version":"1","preferredName":"Chosen Therapeutic Procedure Option Treatment Option Code","preferredDefinition":"The chosen action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process._A system of numbered categories for representation of treatment options.","longName":"4370277v1.0:4370279v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCDDE781-40A9-1C99-E040-BB89AD4366FA","latestVersionIndicator":"Yes","beginDate":"2014-06-27","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-06-27","modifiedBy":"JOOSTENT","dateModified":"2018-04-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4380101","version":"1","preferredName":"Philadelphia Chromosome Cytogenetics Status Stratification Code","preferredDefinition":"The coded value relating to the classification of patients into a sequence of grades or ranks as part of the randomization process, based on the status of the translocation between chromosomes 9 and 22 that is the hallmark for chronic myelogenous leukemia (CML)","longName":"4380013v1.0:4380100v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD3CF7C8-E585-06FF-E040-BB89AD434475","latestVersionIndicator":"Yes","beginDate":"2014-07-02","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-07-02","modifiedBy":"KEARNSD","dateModified":"2014-07-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4442314","version":"1","preferredName":"Mutation Abnormality EGFR Exon 19 Insertion Present Yes No Unknown Indicator","preferredDefinition":"Information related to the presence of the EGFR Exon 19 insertion mutation. Yes/No question regarding information.","longName":"4442313v1.0:3506034v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"000DF624-BC02-6FCE-E050-BB89AD432362","latestVersionIndicator":"Yes","beginDate":"2014-08-07","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-08-07","modifiedBy":"SCOTTM","dateModified":"2014-08-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4442361","version":"1","preferredName":"Asymptomatic Brain Metastasis Present Yes No Indicator","preferredDefinition":"information related to presence of brain metastasis that may or may not be related to symptoms.","longName":"4442357v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"000E94F9-24EB-B64F-E050-BB89AD432A68","latestVersionIndicator":"Yes","beginDate":"2014-08-07","endDate":null,"createdBy":"SCOTTM","dateCreated":"2014-08-07","modifiedBy":"KRYSTKIA","dateModified":"2018-03-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4537853","version":"1","preferredName":"EGFR Gene Assessment Mutation Abnormality Code","preferredDefinition":"The specific EGFR mutation identified.","longName":"3139428v1.0:4537785v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"057B2642-B00A-BAC5-E050-BB89AD4302EA","latestVersionIndicator":"Yes","beginDate":"2014-10-15","endDate":null,"createdBy":"NELSONA","dateCreated":"2014-10-15","modifiedBy":"NELSONA","dateModified":"2014-10-15","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614075","version":"1","preferredName":"Platinum-Based Chemotherapy for Stage I - Stage IIIB Disease Yes No Indicator","preferredDefinition":"The yes/no indicator of use of a platinum-based chemotherapy on Stage I-IIIB disease.","longName":"4614074v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BA5810-B1E6-540A-E050-BB89AD431D80","latestVersionIndicator":"Yes","beginDate":"2014-11-25","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-25","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614091","version":"1","preferredName":"Platinum-Based Chemotherapy Stage I Stage II Stage IIIA Stage IIIB Disease or Disorder Prior Agent Received Text","preferredDefinition":"The free text field for the specification of a platinum-based chemotherapy used for Stage I-IIIB disease.","longName":"4614074v1.0:4273795v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BDCB-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614115","version":"1","preferredName":"Stage I Stage II Stage IIIA Stage IIIB Disease Progression Platinum-Based Chemotherapy Date","preferredDefinition":"The date of progression of Stage I-IIIB disease following a regimen of platinum-based chemotherapy.","longName":"4614114v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08BE25B1-BE26-050B-E050-BB89AD4301A0","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614474","version":"1","preferredName":"Platinum-Based Chemotherapy Stage IV Disease or Disorder Yes No Indicator","preferredDefinition":"The yes/no indicator regarding the use of platinum-based chemotherapy for Stage IV disease.","longName":"4614473v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08CC0D21-14D4-2C05-E050-BB89AD431FCC","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"NELSONA","dateModified":"2015-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614491","version":"1","preferredName":"Platinum-Based Chemotherapy Stage IV Disease or Disorder Prior Agent Received Text","preferredDefinition":"The free text field describing the patient's prior use of platinum-based chemotherapy for Stage IV disease.","longName":"4614473v1.0:4273795v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08CC5E50-1A3E-F63B-E050-BB89AD436E20","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614514","version":"1","preferredName":"Stage IV Disease Progression Platinum-Based Chemotherapy Date","preferredDefinition":"The date of progression of Stage IV disease following a regimen of platinum-based chemotherapy.","longName":"4614513v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08CC5E50-1A96-F63B-E050-BB89AD436E20","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614555","version":"1","preferredName":"Assessment Optical Coherence Tomography Date","preferredDefinition":"The date of an exam using Optical Coherence Tomography (OCT), which combines the principles of ultrasound with the imaging performance of a microscope.","longName":"4614554v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08D00FF6-88F3-8555-E050-BB89AD4321F1","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4614573","version":"1","preferredName":"Urinalysis Assessment Date","preferredDefinition":"The date of a test that determines the content of the urine.","longName":"4614572v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"08D00FF6-892F-8555-E050-BB89AD4321F1","latestVersionIndicator":"Yes","beginDate":"2014-11-26","endDate":null,"createdBy":"KEARNSD","dateCreated":"2014-11-26","modifiedBy":"KEARNSD","dateModified":"2014-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4633935","version":"1","preferredName":"Prior Concurrent Chemoradiotherapy For Nonmetastatic Disease Administered Ind-2","preferredDefinition":"Earlier in time or order._Occurring or operating at the same time._Treatment that combines chemotherapy with radiation therapy._The reason of something._Cancer that has not spread from the primary site (place where it started) to other places in the body._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The act of having given something (e.g., a medication or test)._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4633934v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A4A08AD-FF87-DF1D-E050-BB89AD43041B","latestVersionIndicator":"Yes","beginDate":"2014-12-15","endDate":null,"createdBy":"NELSONA","dateCreated":"2014-12-15","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4633951","version":"1","preferredName":"Prior Concurrent Chemoradiotherapy For Nonmetastatic Disease Administered End Date","preferredDefinition":"Earlier in time or order._Occurring or operating at the same time._Treatment that combines chemotherapy with radiation therapy._The reason of something._Cancer that has not spread from the primary site (place where it started) to other places in the body._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The act of having given something (e.g., a medication or test)._the date on which an observation or an event ended.","longName":"4633934v1.0:2188674v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A4A08AD-FFA7-DF1D-E050-BB89AD43041B","latestVersionIndicator":"Yes","beginDate":"2014-12-15","endDate":null,"createdBy":"NELSONA","dateCreated":"2014-12-15","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682074","version":"1","preferredName":"Regional Lymph Node Metastasis Present Yes No Indicator","preferredDefinition":"Limited to a particular location or area._A bean-shaped organ surrounded by a connective tissue capsule. It is part of the lymphatic system and is found throughout the body. It is composed predominantly of lymphocytes and its main function is immune protection._The spread or migration of cancer cells from one part of the body (the organ in which it first appeared) to another. The secondary tumor contains cells that are like those in the original (primary) tumor._Being or existing in a specified place or at the specified time._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4682073v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"RTOG CRF:Radiation Therapy Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9685D8-4E59-3F3B-E050-BB89AD432836","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Replaced VD Involvement Extent Disease Ind-2 - 2180012v1 with VD ID#3506068 - Yes No Indicator - dbw. Released AN 7/8/15.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682134","version":"1","preferredName":"Disease Assessment Type","preferredDefinition":"information related to the examination of the body by auscultation, palpation, percussion, inspection, and olfaction for any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person._Something distinguishable as an identifiable class based on common qualities.","longName":"2178332v2.0:4682131v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D975F4D-106E-1D0A-E050-BB89AD430D5D","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682151","version":"1","preferredName":"Laboratory Procedure CD4 Expressing Cell Count Outcome Date","preferredDefinition":"The outcome of the procedure to determine the amount of the CD4 expressing cells in a sample._the date on which an observation was made or an event occurred.","longName":"4182741v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-34F2-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682152","version":"1","preferredName":"Human Immunodeficiency Virus Viral Load Assay Outcome Date","preferredDefinition":"The result of analysis performed to determine the amount of viral particles (HIV) in a sample of blood plasma._the date on which an observation was made or an event occurred.","longName":"4182774v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3511-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682185","version":"1","preferredName":"Regional Metastasis First Diagnosis Date","preferredDefinition":"related to the initial process of identifying spread of cancer from the anatomic location where it first appeared to adjacent or in-transit structures._Limited to a particular location or area._the date on which an observation was made or an event occurred.","longName":"4682169v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"CTEP CDE Committee","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3876-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"updated for ISO compliance. Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682186","version":"1","preferredName":"PDL1/PD1 Pharmacologic Substance Status","preferredDefinition":"Information related to PDL1/PD1 inhibitor administered_Category; used informally to mean a class of things.","longName":"4606913v1.0:4214015v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-3897-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4682211","version":"1","preferredName":"First Disease Progression Relapse Date","preferredDefinition":"First documentation of a progression or relapse of the disease/condition under investigation._the date on which an observation was made or an event occurred.","longName":"2190405v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D9795AD-38B6-01BE-E050-BB89AD43364B","latestVersionIndicator":"Yes","beginDate":"2015-01-26","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-01-26","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701933","version":"1","preferredName":"Patient Quality of Life Consent Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator regarding information related to a person who receives medical attention, care, or treatment, giving permission for questions concerning Quality of Life.","longName":"PT_QOL_CON_IND3","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E4C89A0-8CB9-4363-E050-BB89AD433845","latestVersionIndicator":"Yes","beginDate":"2015-02-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-02-04","modifiedBy":"JOOSTENT","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4701934","version":"1","preferredName":"Patient Ancillary Study Questionnaire Specimen Consent Yes No Not Applicable Indicator","preferredDefinition":"The yes/no/not applicable indicator regarding information related to consent obtained from a patient to take part in, and provide research specimens for, a clinical protocol which is secondary to another protocol in which the individual is already enrolled.","longName":"3654010v1.0:3506036v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E4C89A0-8CE2-4363-E050-BB89AD433845","latestVersionIndicator":"Yes","beginDate":"2015-02-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-02-04","modifiedBy":"JOOSTENT","dateModified":"2017-10-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4704275","version":"1","preferredName":"Laboratory Procedure BRAF Gene Mutation Abnormality Present Outcome Yes No Unknown Indicator","preferredDefinition":"A laboratory procedure testing for the presence of a mutation of the BRAF gene, a gene involved in cell organization/biogenesis and the inhibition of apoptosis._The preferred Value Domain to indicate a question with permissible values of yes/no/unknown.","longName":"4360374v1.0:3506034v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E5F0038-F682-E299-E050-BB89AD434485","latestVersionIndicator":"Yes","beginDate":"2015-02-05","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-02-05","modifiedBy":"MORENOC","dateModified":"2019-12-05","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4715175","version":"1","preferredName":"Prior Biological Therapy Administered Date","preferredDefinition":"information related to biological therapy administered previously._the date on which an observation was made or an event occurred.","longName":"2190855v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EC3FE6B-F195-7B80-E050-BB89AD4323F8","latestVersionIndicator":"Yes","beginDate":"2015-02-10","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-02-10","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4715286","version":"1","preferredName":"Prior Immunotherapy Administered Date","preferredDefinition":"Earlier in time or order._(IM-yoo-no-THER-a-pee) Treatment to stimulate or restore the ability of the immune system to fight infections and other diseases. Also used to lessen side effects that may be caused by some cancer treatments._The act of having given something (e.g., a medication or test)._the date on which an observation was made or an event occurred.","longName":"3774272v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0EC4E38D-4B5A-5FB7-E050-BB89AD4365E8","latestVersionIndicator":"Yes","beginDate":"2015-02-10","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-02-10","modifiedBy":"HARTLEYG","dateModified":"2016-04-04","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4719111","version":"1","preferredName":"Patient Clinical Trial Protocol Cancer Progression Date","preferredDefinition":"information related to cancer progression, worsening of a cancer over time, according to the protocol, an action plan for a clinical trial that states what the study will do, how, and why, by a patient/participant._the date on which an observation was made or an event occurred.","longName":"2640590v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0F52252A-1910-2AF4-E050-BB89AD437D8B","latestVersionIndicator":"Yes","beginDate":"2015-02-17","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-02-17","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4731395","version":"1","preferredName":"Patient Prior Therapy Disease Progression Yes No Indicator","preferredDefinition":"The yes/no indicator of whether a person has been previously treated for the same condition or with the same therapy and there has been a worsening of a disease over time.","longName":"4731394v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"106486C0-E134-F3E0-E050-BB89AD433A15","latestVersionIndicator":"Yes","beginDate":"2015-03-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-03","modifiedBy":"SPRINGERL","dateModified":"2020-05-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4732851","version":"1","preferredName":"Therapeutic Procedure First-Line Platinum-Based Chemotherapy Cycle Number","preferredDefinition":"Number of therapeutic cycles of the preferred standard chemotherapy that is derived from or containing platinum and used as treatment for a particular condition to produce an effect that is intended to alter or stop a pathologic process.","longName":"4732827v1.0:4732835v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"106B6589-9F68-E0BA-E050-BB89AD43746C","latestVersionIndicator":"Yes","beginDate":"2015-03-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-03","modifiedBy":"STARGELM","dateModified":"2020-09-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4732871","version":"1","preferredName":"Docetaxel Administered Last Date","preferredDefinition":"The last date a treatment using a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata, was administered.","longName":"2867153v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"106B6589-9FCF-E0BA-E050-BB89AD43746C","latestVersionIndicator":"Yes","beginDate":"2015-03-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-03","modifiedBy":"KEARNSD","dateModified":"2015-03-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4736043","version":"1","preferredName":"Radiation Therapy Localized Palliative Administered Yes No Indicator","preferredDefinition":"The yes/no indicator for the administration of radiation therapy that is restricted to the site of origin without evidence of spread and without curative intent in order to mitigate some or all of the unpleasant effects of a disease or condition.","longName":"4736042v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1091F977-D2FB-E7DA-E050-BB89AD43765A","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-05","modifiedBy":"SARAHB","dateModified":"2019-01-03","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4736047","version":"1","preferredName":"Radiation Therapy Localized Palliative Administered Last Date","preferredDefinition":"The last date of the administration of radiation therapy that is restricted to the site of origin without evidence of spread and without curative intent in order to mitigate some or all of the unpleasant effects of a disease or condition.","longName":"4736042v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10920CAD-5424-806E-E050-BB89AD434668","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-05","modifiedBy":"KEARNSD","dateModified":"2015-03-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4736058","version":"1","preferredName":"Radiation Therapy Cure Intent Administered Yes No Indicator","preferredDefinition":"The yes/no indicator for the administration of radiation therapy with the intention of remedying or restoring health.","longName":"4736053v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1091F977-D37B-E7DA-E050-BB89AD43765A","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-05","modifiedBy":"ZIEGLERK","dateModified":"2015-05-12","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4736060","version":"1","preferredName":"Radiation Therapy Cure Intent Administered Last Date","preferredDefinition":"The last date of the administration of radiation therapy with the intention of remedying or restoring health.","longName":"4736053v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1091F977-D3EA-E7DA-E050-BB89AD43765A","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-05","modifiedBy":"KEARNSD","dateModified":"2015-03-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4736146","version":"1","preferredName":"Prior Therapy Administered Number Stratification Code","preferredDefinition":"The codes representing the classification of patients into groups according to the number of prior therapies received, as part of the randomization process,","longName":"2197794v1.0:4736145v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10937DFF-258B-4143-E050-BB89AD434398","latestVersionIndicator":"Yes","beginDate":"2015-03-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-03-05","modifiedBy":"KEARNSD","dateModified":"2015-03-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4755169","version":"1","preferredName":"Immune Adverse Event Present Yes No Indicator","preferredDefinition":"information relating to the presence of a vaccine-related (administration of vaccines to stimulate the host's immune response) adverse event (any unfavorable and unintended sign, including an abnormal laboratory finding, symptom, syndrome, or disease)._Protected against infectious disease by either specific or non-specific mechanisms._A state of connectedness between people, objects, or events; to be associated or connected with something._Being or existing in a specified place or at the specified time._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4755148v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"121079B0-1BF4-AC68-E050-BB89AD434CD9","latestVersionIndicator":"Yes","beginDate":"2015-03-24","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-03-24","modifiedBy":"COOPERM","dateModified":"2017-11-21","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4783233","version":"1","preferredName":"PD-L1 Status","preferredDefinition":"Information related to PDL1/PD1 inhibitor administered_Category; used informally to mean a class of things._Cannot distinguish between two or more possible values in the current context._Unable to be evaluated.","longName":"4606913v1.0:4753832v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"132B2A2D-BAA7-4BD9-E050-BB89AD433208","latestVersionIndicator":"Yes","beginDate":"2015-04-07","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-04-07","modifiedBy":"MORENOC","dateModified":"2021-06-22","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4791294","version":"1","preferredName":"Tumor Tissue Specimen Storage Future Use Consent Yes No Indicator","preferredDefinition":"The yes/no indicator relating to consent for tumor tissue specimen storage for future use.","longName":"4791293v1.0:2018303v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"13A3F4B0-83FC-9613-E050-BB89AD436764","latestVersionIndicator":"Yes","beginDate":"2015-04-13","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-13","modifiedBy":"KEARNSD","dateModified":"2021-03-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798631","version":"1","preferredName":"Programmed Cell Death 1 Ligand 1 Protein Status Status","preferredDefinition":"Status of the programmed cell death 1 ligand 1 (290 aa, ~33 kDa), which is encoded by the human CD274 gene. This protein is involved in the mediation of both the activation and proliferation of T cells.","longName":"4798533v1.0:4798611v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"145CF5D9-681B-1F05-E050-BB89AD4304B6","latestVersionIndicator":"Yes","beginDate":"2015-04-22","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-22","modifiedBy":"COOPERM","dateModified":"2018-02-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798932","version":"1","preferredName":"Specimen Acceptable Tissue Morphology Submission Yes No Indicator","preferredDefinition":"The yes/no indicator of the acceptability as submitted of the specific appearance of cells and tissues (normal and abnormal) under the light or electron microscope.","longName":"4798930v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"146B9AA2-6B4D-EBC1-E050-BB89AD431F42","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-23","modifiedBy":"KEARNSD","dateModified":"2015-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798943","version":"1","preferredName":"Specimen Acceptable Background Staining Method Submission Yes No Indicator","preferredDefinition":"The yes/no indicator of acceptability of the background staining of a specimen submission.","longName":"4798942v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"146CB4EC-E20D-6E94-E050-BB89AD4322BC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-23","modifiedBy":"KEARNSD","dateModified":"2015-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798991","version":"1","preferredName":"Pathology Tissue Specimen Membrane Stain Neoplasm Cell Percentage Value","preferredDefinition":"a fraction with the denominator 100 representing a quantity of cells from a sample of tissue or body fluid dyed for microscopic assessment of disease by a specialist in cellular function and changes.","longName":"4798973v1.0:2018830v2.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1471677E-60AD-1898-E050-BB89AD4308CC","latestVersionIndicator":"Yes","beginDate":"2015-04-23","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-24","modifiedBy":"SOKKERL","dateModified":"2022-02-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4798995","version":"1","preferredName":"Pathology Specimen Neoplasm Immune Cell Percentage Value","preferredDefinition":"the numerical quantity measured or assigned or computed as a fraction or ratio with 100 understood as the denominator and related to tumor immune cells during microscopic assessment of a sample of tissue by a specialist in cellular function and changes.","longName":"4798994v1.0:2019325v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1471677E-60F8-1898-E050-BB89AD4308CC","latestVersionIndicator":"Yes","beginDate":"2015-04-24","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-24","modifiedBy":"KEARNSD","dateModified":"2015-04-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4799294","version":"1","preferredName":"Pathology Specimen Positive Programmed Cell Death 1 Ligand 1 Neoplasm Immune Cell Percentage Value","preferredDefinition":"the numerical quantity measured or assigned or computed as a fraction or ratio with 100 understood as the denominator and relating to the finding of positive PD-L1 (a protein involved in the mediation of both the activation and proliferation of T cells) tumor immune cells in a specimen.","longName":"4799293v1.0:2019325v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"147F3281-48A6-7CB9-E050-BB89AD43712C","latestVersionIndicator":"Yes","beginDate":"2015-04-24","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-04-24","modifiedBy":"KRYSTKIA","dateModified":"2018-09-14","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4810294","version":"1","preferredName":"Third Alternative Contact Person E-mail Address Text","preferredDefinition":"The free-text field related to the email address of a third alternative contact person","longName":"4810293v1.0:4293535v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"154EB665-6465-8DA1-E050-BB89AD435AAC","latestVersionIndicator":"Yes","beginDate":"2015-05-04","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-05-05","modifiedBy":"KEARNSD","dateModified":"2015-05-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4859710","version":"1","preferredName":"Melanoma Specimen Inadequate Reason","preferredDefinition":"A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis._Not meeting a quantitative or qualitative measure necessary for a requirement._An explanation of the cause of some phenomenon or action.","longName":"4859709v1.0:4858178v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18091439-4D61-6A8E-E050-BB89AD432754","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-08","modifiedBy":"NELSONA","dateModified":"2015-07-08","changeNote":"Released AN 7/8/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4882034","version":"1","preferredName":"Nivolumab Administered Yes No Indicator","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4882033v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18D28FE9-69BD-68CC-E050-BB89AD437B6D","latestVersionIndicator":"Yes","beginDate":"2015-06-18","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-18","modifiedBy":"ZHWENDY","dateModified":"2022-09-21","changeNote":"released as part of draft content review - DH, 12-28-15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4882035","version":"1","preferredName":"Nivolumab Administered Last Date","preferredDefinition":"A fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1/PCD-1) with immunopotentiation activity. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands PD-L1 and PD-L2, resulting in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and effector function through the suppression of P13k/Akt pathway activation._the last date of an evaluation, assessment, or treatment.","longName":"4882033v1.0:2192181v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18D2B54D-BEBD-0030-E050-BB89AD43049F","latestVersionIndicator":"Yes","beginDate":"2015-06-18","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-18","modifiedBy":"KEARNSD","dateModified":"2015-12-28","changeNote":"released as part of draft content review - DH, 12-28-15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4888131","version":"1","preferredName":"PDL1/PD1 Pharmacologic Substance Administered Lab Condition Specimen Type","preferredDefinition":"Information related to PDL1/PD1 inhibitor administered_a description of the usable condition or status of a specimen upon receipt after transport from another location.","longName":"4606913v1.0:2015446v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"196012E7-239B-7AB9-E050-BB89AD430662","latestVersionIndicator":"Yes","beginDate":"2015-06-25","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-06-25","modifiedBy":"KEARNSD","dateModified":"2015-12-28","changeNote":"released as part of draft content review - DH, 12-28-15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4916494","version":"1","preferredName":"Southwest Oncology Group Patient Clinical Study Biopsy Participation Yes No Not Applicable Indicator","preferredDefinition":"the yes/no/not applicable indicator of a patient's consent for SWOG biopsy participation in order to discover facts, to establish or revise a theory, or to develop a plan of action based on the biopsy.","longName":"4916493v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B69FCD0-9AC8-6D22-E050-BB89AD433F78","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-07-21","modifiedBy":"KEARNSD","dateModified":"2015-11-24","changeNote":"Updated on 11/24/15 to include the option of NA.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"4962535","version":"1","preferredName":"Patient Pretreatment Pregnancy Test Date","preferredDefinition":"information relating to the most recent pregnancy test of a patient._Any relevant actions that were performed or occurred prior to a specific treatment._the date on which an observation was made or an event occurred.","longName":"4962533v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1D382490-F1FC-7674-E050-BB89AD437B19","latestVersionIndicator":"Yes","beginDate":"2015-08-13","endDate":null,"createdBy":"NELSONA","dateCreated":"2015-08-13","modifiedBy":"JOOSTENT","dateModified":"2017-11-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5040535","version":"1","preferredName":"Patient Trial Screening Status","preferredDefinition":"A patient's trial screening status at a particular time._The state of the process of active consideration of a potential subject for enrollment in a trial at a particular time.","longName":"5040530v1.0:5040532v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"23461EB1-9232-9805-E050-BB89AD432CE6","latestVersionIndicator":"Yes","beginDate":"2015-10-29","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-10-29","modifiedBy":"KEARNSD","dateModified":"2015-10-30","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5092048","version":"1","preferredName":"Mutation Abnormality KRAS Gene Assessment Stratification Code","preferredDefinition":"The stratification code for the assessment of any transmissible change in the KRAS gene, a gene involved in signal transduction and apoptosis.","longName":"5092044v1.0:5092046v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2731F2FC-7188-6BDB-E050-BB89AD430BD8","latestVersionIndicator":"Yes","beginDate":"2015-12-18","endDate":null,"createdBy":"KEARNSD","dateCreated":"2015-12-18","modifiedBy":"KEARNSD","dateModified":"2015-12-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5126701","version":"1","preferredName":"Patient Behavior Health Outcome Consent Yes No Indicator","preferredDefinition":"a yes/no question related to consent for participation in Behavioral and Health Outcomes study","longName":"5126592v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C25939A-7732-9BCB-E050-BB89AD4318A6","latestVersionIndicator":"Yes","beginDate":"2016-02-19","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2016-02-19","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5126877","version":"1","preferredName":"Nodal Stage","preferredDefinition":"information relating to process of classifying patients into strata as part of the randomization process of the action plan for a clinical trial by nodal status._the coded value related to the nodal status of a patient","longName":"5126873v1.0:5126874v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C26A48D-1F1F-FE81-E050-BB89AD436B46","latestVersionIndicator":"Yes","beginDate":"2016-02-19","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2016-02-19","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5126898","version":"1","preferredName":"Tumor Size Stratification Code","preferredDefinition":"the coded value related to the tumor size of a patient","longName":"2014104v1.0:5126893v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C26A48D-1FA6-FE81-E050-BB89AD436B46","latestVersionIndicator":"Yes","beginDate":"2016-02-19","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2016-02-19","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5272011","version":"1","preferredName":"Blood Specimen Storage Future Use Consent Yes No Indicator","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis_The act of safekeeping goods in a depository._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._Permission to do something.__A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5271997v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"334AA133-21A0-3B5E-E050-BB89AD4310A0","latestVersionIndicator":"Yes","beginDate":"2016-05-20","endDate":null,"createdBy":"NELSONA","dateCreated":"2016-05-20","modifiedBy":"JOOSTENT","dateModified":"2017-11-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5275511","version":"2","preferredName":"Southwest Oncology Group Patient Clinical Study Biopsy Participation Yes No Indicator","preferredDefinition":"the Southwest Oncology Group, an NCI-sponsored adult cancer clinical trials organization, patient's consent to systematic investigation into a subject in order to discover facts, to establish or revise a theory, or to develop a plan of action based on the biopsy._The act of taking part in an activity._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"4916493v1.0:5262035v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91BE0D74-8170-6C78-E053-F662850A8E3B","latestVersionIndicator":"Yes","beginDate":"2016-05-23","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-09-04","modifiedBy":"HARTLEYG","dateModified":"2019-09-04","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5300444","version":"1","preferredName":"Patient Histologic Cohort Stratification Code","preferredDefinition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._A group of individuals, identified by a common characteristic._The coded value representing the combined microscopic physical features of cells and their surrounding extracellular environment in tissues, used in the process of classifying patients into strata as part of the randomization process or for purposes of data analysis.","longName":"5299926v1.0:5300413v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35811F66-1FF1-C498-E050-BB89AD4369C2","latestVersionIndicator":"Yes","beginDate":"2016-06-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-06-17","modifiedBy":"KEARNSD","dateModified":"2020-05-06","changeNote":"Updated text of multiple VDs - 10/3/16, DH Added 4 new VDs - 10/25/17, DH; Updated text of 3 VDs - 10/25/17, DH; Updated typo in VD 27 - 11/16/17, DH; Added 16 new VDs - 6/18/18, DH; Added new text for the 16 new VDs - 5/22/19, DH; Added new text for cohort 45 - 6/18/19, DH; Added new text for cohort 50 - 5/6/20, DH;","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5300453","version":"1","preferredName":"Patient Prior Clinical Study Identifier","preferredDefinition":"Unique identifier for a patient on a prior protocol/clinical trial.","longName":"5300452v1.0:2016938v3.1","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3581F9D0-B08B-DBCB-E050-BB89AD433DA8","latestVersionIndicator":"Yes","beginDate":"2016-06-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2016-06-17","modifiedBy":"KEARNSD","dateModified":"2016-06-17","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5426091","version":"1","preferredName":"Laboratory Procedure HER2/neu Chromosome 17 Probe Fluorescence In Situ Hybridization Performed HER2/CEP17 Ratio Stratification Code","preferredDefinition":"information related to the result of the medical procedure that involves testing a sample of blood or tissue for the ration of HER2/NEU and chromosome enumeration probe 17,  a piece of Chromosome 17 that has been labelled either radioactively or with some other detectable molecule, such as biotin, digoxygenin or fluorescein, using Fluorescence In Situ Hybridization, a physical mapping approach that uses fluorescent tags to detect hybridization of probes within metaphase chromosomes or less condensed somatic interphase chromatin._the coded value related to the HER2/CEP17 Ratio of a patient_The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"3155925v1.0:5408118v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3A72F92C-C53F-620E-E050-BB89AD4363BC","latestVersionIndicator":"Yes","beginDate":"2016-08-19","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2016-08-19","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5427831","version":"1","preferredName":"Heart Baseline Left Ventricular Ejection Fraction Test Stratification Code","preferredDefinition":"information related to the initial measure of how much blood the left ventricle of the heart pumps out with each contraction._the coded value related to the baseline ejection fraction of a patient_The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"2519956v1.0:5427811v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3AAC3C22-1575-E028-E050-BB89AD432625","latestVersionIndicator":"Yes","beginDate":"2016-08-22","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2016-08-22","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5511116","version":"1","preferredName":"Urine Specimen Storage Future Use Consent Yes No Indicator","preferredDefinition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis_The act of safekeeping goods in a depository._Use; put into service; make work or employ (something) for a particular purpose or for its inherent or natural purpose._Permission to do something.__The fluid that is excreted by the kidneys.  It is stored in the bladder and discharged through the urethra._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5511091v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3EB3E59C-7E5C-3563-E053-F662850A0E7A","latestVersionIndicator":"Yes","beginDate":"2016-10-12","endDate":null,"createdBy":"NELSONA","dateCreated":"2016-10-12","modifiedBy":"JOOSTENT","dateModified":"2017-11-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5598424","version":"1","preferredName":"Biopsy Cutaneous Superficial Lesion Yes No Indicator","preferredDefinition":"The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis._Having to do with the skin._Of little substance or significance; involving only a surface._(LEE-zhun) An area of abnormal tissue change._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"5598423v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4329FE53-E64D-4EFD-E053-F662850AAF64","latestVersionIndicator":"Yes","beginDate":"2016-12-08","endDate":null,"createdBy":"NELSONA","dateCreated":"2016-12-08","modifiedBy":"JOOSTENT","dateModified":"2017-11-08","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5676180","version":"1","preferredName":"Previous Study Assignment Patient Identifier Descriptive Text","preferredDefinition":"Occurring prior to something else._A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it._An allotting or an appointment to a particular person or use, or for a particular time or object._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._The text that provides a description of a topic.","longName":"5676179v1.0:2181231v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4923FAAA-F07C-509A-E053-F662850A71EA","latestVersionIndicator":"Yes","beginDate":"2017-02-22","endDate":null,"createdBy":"NELSONA","dateCreated":"2017-02-22","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeNote":null,"administrativeNotes":"6/27/22 added AQT for SWOG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5724649","version":"1","preferredName":"Informed Consent Form Version Date","preferredDefinition":"Consent by a patient to a surgical or medical procedure or participation in a clinical study after achieving an understanding of the relevant medical facts and the risks involved._A printed or electronic document with spaces to be filled out._The particular day, month and year an event has happened or will happen._A form or variant of a type or original; one of a sequence of copies of a program, each incorporating new modifications._the date on which an observation was made or an event occurred.","longName":"5724648v1.0:2018550v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4B6E476C-987E-6A52-E053-F662850AA0C1","latestVersionIndicator":"Yes","beginDate":"2017-03-23","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2017-03-23","modifiedBy":"KEARNSD","dateModified":"2021-08-18","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5982776","version":"1","preferredName":"Southwest Oncology Group Patient Research Biopsy Consent Yes No Not Applicable Indicator","preferredDefinition":"the Southwest Oncology Group, an NCI-sponsored adult cancer clinical trials organization, patient's consent to systematic investigation into a subject in order to discover facts, to establish or revise a theory, or to develop a plan of action based on the biopsy._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"3153212v1.0:3506036v1.1","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A67302-87B4-3D64-E053-F662850A0A45","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2017-09-20","modifiedBy":"KEARNSD","dateModified":"2018-03-20","changeNote":"Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5982777","version":"1.1","preferredName":"Southwest Oncology Group Patient Research Biopsy Consent Yes No Not Applicable Indicator","preferredDefinition":"the Southwest Oncology Group, an NCI-sponsored adult cancer clinical trials organization, patient's consent to systematic investigation into a subject in order to discover facts, to establish or revise a theory, or to develop a plan of action based on the biopsy._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"3153212v1.0:3506036v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"59A6827C-DA98-3D74-E053-F662850A1D97","latestVersionIndicator":"Yes","beginDate":"2017-09-20","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2017-09-20","modifiedBy":"KEARNSD","dateModified":"2018-03-20","changeNote":"Replaced VD Patient Consent Ind-2 2018303v1.0 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5984242","version":"1","preferredName":"Tissue Specimen Type Tissue Submission Type","preferredDefinition":"is an organ part that consists of similarly specialized cells and intercellular matrix, aggregated according to specific spatial relationships; together with other tissues, it constitutes an organ component. Example(s): epithelium, muscle(tissue), connective tissue, neural tissue, lymphoid tissue.:Specimen; a bit of tissue or blood or urine that is taken or used for research purposes._A subdivision of a particular kind of thing._An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function._The act of referring for judgment or consideration by others; the act of handing over something._Something distinguishable as an identifiable class based on common qualities.","longName":"2513570v1.0:5984239v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5A451E6D-690A-04A3-E053-F662850ABDF2","latestVersionIndicator":"Yes","beginDate":"2017-09-28","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2017-09-28","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5988421","version":"1","preferredName":"Therapeutic Procedure Prior Tyrosine Kinase Inhibitor Administered Duration Stratification Code","preferredDefinition":"A coded value representing the stratification of duration.","longName":"Prior TKI Duration Strat Code","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD06862-C748-79DB-E053-F662850AC45B","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2017-10-05","modifiedBy":"KEARNSD","dateModified":"2020-02-12","changeNote":"For use in S1712 OPEN registration worksheet; add new value for 1st strat factor (>=4) - 2/12/20, DH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"5989304","version":"1","preferredName":"Current Tyrosine Kinase Inhibitor Administered Stratification Code","preferredDefinition":"Occurring in or belonging to the present time._Any substance that inhibits tyrosine kinase, an enzyme involved in the transduction and processing of many extracellular and intracellular signals including cell proliferation. Inhibition of tyrosine kinase may result in inhibition of cell growth and cell proliferation._The act of having given something (e.g., a medication or test)._the stratification code classifying the type of TKI","longName":"CUR_TKI_STRAT_CODE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5AD191C5-59D2-3B8D-E053-F662850A1417","latestVersionIndicator":"Yes","beginDate":"2017-10-05","endDate":null,"createdBy":"KEARNSD","dateCreated":"2017-10-05","modifiedBy":"KEARNSD","dateModified":"2021-01-13","changeNote":"Added VD \"Bosutinib\" - 8/20/19, DH; Added VD \"Imatinib\" - 1/13/2021, DH","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6032733","version":"1","preferredName":"Patient Consent Additional  Biopsy Cancer Biobank Yes No Indicator","preferredDefinition":"Added; extra; further._A repository of biospecimens - including tissue samples, fluids such as blood, serum and urine, and molecular derivatives such as DNA, RNA and proteins pertaining to cancer research. The repository has stringent guidelines regarding the standardized collection, handling, storage and documentation of biological specimens. These guidelines enable an extensive system for specimen storage that allows for the accurate establishment of disease incidences over long periods of time._The removal of tissue specimens or fluid from the living body for microscopic examination, performed to establish a diagnosis._Permission to do something._Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"6032732v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5EFC7424-76D0-2F2A-E053-F662850A9F5D","latestVersionIndicator":"Yes","beginDate":"2017-11-27","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2017-11-27","modifiedBy":"NELSONA","dateModified":"2020-01-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6053734","version":"1","preferredName":"Patient Future Communication Consent Yes No Not Applicable Indicator","preferredDefinition":"information related to patient contact consent._The preferred Value Domain to indicate a question with permissible values of yes/no/not applicable.","longName":"2189905v1.0:3506036v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"63638F18-977C-1284-E053-F662850ADFD3","latestVersionIndicator":"Yes","beginDate":"2018-01-22","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2018-01-22","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6144838","version":"1","preferredName":"Lung Histology Squamous Cell Carcinoma Non-Squamous Non-Small Cell Lung Carcinoma Type","preferredDefinition":"One of a pair of viscera occupying the pulmonary cavities of the thorax, the organs of respiration in which aeration of the blood takes place. As a rule, the right lung is slightly larger than the left and is divided into three lobes (an upper, a middle, and a lower or basal), while the left has two lobes (an upper and a lower or basal). Each lung is irregularly conical in shape, presenting a blunt upper extremity (the apex), a concave base following the curve of the diaphragm, an outer convex surface (costal surface), an inner or mediastinal surface (mediastinal surface), a thin and sharp anterior border, and a thick and rounded posterior border._The study of the structure of the cells and their arrangement to constitute tissues and, finally, the association among these to form organs.  In pathology, the microscopic process of identifying normal and abnormal morphologic characteristics in tissues, by employing various cytochemical and immunocytochemical stains._A carcinoma arising from squamous epithelial cells.  Morphologically, it is characterized by the proliferation of atypical, often pleomorphic squamous cells.  Squamous cell carcinomas are graded by the degree of cellular differentiation as well, moderately, or poorly differentiated.  Well differentiated carcinomas are usually associated with keratin production and the presence of intercellular bridges between adjacent cells.  Representative examples are lung squamous cell carcinoma, skin squamous cell carcinoma, and cervical squamous cell carcinoma._A non-small cell lung carcinoma without evidence of squamous differentiation._Something distinguishable as an identifiable class based on common qualities.","longName":"5434035v1.0:6144833v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68046AA4-DCA0-78F2-E053-F662850A8A13","latestVersionIndicator":"Yes","beginDate":"2018-03-22","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2018-03-22","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6144841","version":"1","preferredName":"Southwest Oncology Group Patient Research Consent Ind-2","preferredDefinition":"the yes/no indicator that asks if the Southwest Oncology Group patient has agreed to future contact regarding future research and participation in the current study.","longName":"SWOG_PT_RSCH_CON_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"68046B14-C7E8-02BC-E053-F662850AD8DF","latestVersionIndicator":"Yes","beginDate":"2018-03-22","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2018-03-22","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":"Replaced Protocol Administration Ind-2 2018304v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6270972","version":"1","preferredName":"Hepatitis B Status Stratification Code","preferredDefinition":"The stratification code categorizing the status of a viral hepatitis caused by the Hepatitis B virus (HBV).","longName":"2931632v1.0:6270969v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9E6B8-AEE6-5E5B-E053-F662850ADD47","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6272113","version":"1","preferredName":"Malignant Neoplasm Therapeutic Procedure Plan Description Stratification Code","preferredDefinition":"Stratification code representing a type of therapy.","longName":"6272106v1.0:6272108v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9B0E6-5382-3803-E053-F662850A0070","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"KEARNSD","dateModified":"2021-07-19","changeNote":"Added alternate question text and 2 permissible values - 04/30/21, DH; Added alternate question text and 2 permissible values - 07/15/21, DH; Added 1 permissible value - 07/19/21, DH;","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6272121","version":"1","preferredName":"Hepatitis B Surface Antibody Measurement Description Stratification Code","preferredDefinition":"The stratification code representing the status of the surface antibody reaction of a sample to the Hepatitis B virus (Anti-HBs).","longName":"6272116v1.0:6272118v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6BB9E0CF-0AC8-212D-E053-F662850AA782","latestVersionIndicator":"Yes","beginDate":"2018-05-08","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-05-08","modifiedBy":"AUGERG","dateModified":"2021-05-06","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6338364","version":"1","preferredName":"Standard Systemic Therapy Chemotherapy Yes No Indicator","preferredDefinition":"A document, established by consensus and approved by a recognized body, that provides, for common and repeated use, rules, guidelines or characteristics for activities or their results._Affecting the entire body._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process._The use of synthetic or naturally-occurring chemicals for the treatment of diseases._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"6338362v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6F2CE729-5EB5-3E30-E053-F662850AD971","latestVersionIndicator":"Yes","beginDate":"2018-06-21","endDate":null,"createdBy":"NELSONA","dateCreated":"2018-06-21","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6343595","version":"1","preferredName":"Dose Count Approval Dose Chairperson Study Yes No Indicator","preferredDefinition":"Number of doses or individual administrations of an agent or measure given to a person._Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval._Specified quantity of a medicine, to be taken at one time or at stated intervals. [ISO 11615:2012 Health Informatics]_The officer who presides at the meetings of an organization, committee, or other organizational structure._A detailed examination, analysis, or critical inspection of a subject designed to discover facts about it._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"6343591v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6FA08193-0FD4-6294-E053-F662850A8213","latestVersionIndicator":"Yes","beginDate":"2018-06-27","endDate":null,"createdBy":"NELSONA","dateCreated":"2018-06-27","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6369842","version":"1","preferredName":"Clinical Study Site Research Personnel Staff Identifier Text","preferredDefinition":"The identifying name of a person working at a clinical research facility.","longName":"2992788v1.0:2761953v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"71C718D4-D3A2-0E77-E053-F662850A0B47","latestVersionIndicator":"Yes","beginDate":"2018-07-24","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-07-24","modifiedBy":"AUGERG","dateModified":"2020-01-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6400642","version":"1","preferredName":"Patient Biopsy Non-Small Cell Lung Carcinoma Histologic Type","preferredDefinition":"information relating to a patient biopsy and non-small cell lung cancer._Pertaining to the combined microscopic physical features of cells and their surrounding extracellular environment in tissues._Something distinguishable as an identifiable class based on common qualities.","longName":"2201375v1.0:6400638v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"736C4D32-B98B-37FA-E053-F662850A43CC","latestVersionIndicator":"Yes","beginDate":"2018-08-14","endDate":null,"createdBy":"ANDERSONR","dateCreated":"2018-08-14","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483023","version":"1","preferredName":"Tumor Planned Surgery Yes No Indicator","preferredDefinition":"A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues.  Malignant neoplasms usually metastasize to distant anatomic sites and may recur after excision.  The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin's and non-Hodgkin's lymphomas, leukemias, melanomas, and sarcomas. -- 2004_To devise, contrive, or form in design._A diagnostic or treatment procedure performed by manual and/or instrumental means, often involving an incision and the removal or replacement of a diseased organ or tissue; of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"3440168v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"784A95B8-9A72-72F7-E053-F662850A9398","latestVersionIndicator":"Yes","beginDate":"2018-10-15","endDate":null,"createdBy":"NELSONA","dateCreated":"2018-10-15","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6483225","version":"1","preferredName":"Planned Surgery Neoadjuvant Therapy CTMS Date","preferredDefinition":"Particular day specified when a surgical procedure is planned to occur._Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy._Date as required for Clinical Trials Monitoring Service submissions.  Exchange format is YYYYMMDD.  Display format is DDMMMYYYY, with the month display the first three letters of each month (Jan, Feb, Mar, etc.).","longName":"6483224v1.0:2017121v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"785ED2AE-1517-3006-E053-F662850A71CB","latestVersionIndicator":"Yes","beginDate":"2018-10-16","endDate":null,"createdBy":"NELSONA","dateCreated":"2018-10-16","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6582787","version":"1","preferredName":"Radiation Therapy Type","preferredDefinition":"The free-text description of the type of radiation therapy.","longName":"2012436v3.0:6582786v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C6228AA-91CB-480A-E053-F662850A7651","latestVersionIndicator":"Yes","beginDate":"2018-12-06","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-12-06","modifiedBy":"AUGERG","dateModified":"2020-01-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6594237","version":"1","preferredName":"Multiple Myeloma Disease Stage Stratification Code","preferredDefinition":"information relating to the stratification code representing the stage of a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","longName":"2465384v1.0:6594234v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D3DECE1-B35B-53E2-E053-F662850ABA3A","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-12-17","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6594250","version":"1","preferredName":"Autologous Hematopoietic Stem Cell Transplantation Disease Response Assessment Stratification Code","preferredDefinition":"Stratification code representing the response to stem cell transfer or transplantation in which the patient is his own donor.","longName":"6594245v1.0:6594247v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D410CC5-5D7C-161E-E053-F662850AE1EA","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-12-17","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":"Add updated strat factor #1- DH, 12/20/18","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6596998","version":"1","preferredName":"Clinical Trial Protocol Chemotherapy Administered Regimen Stratification Code","preferredDefinition":"The stratification code that represents an administered chemotherapy regimen.","longName":"2014785v3.0:6596996v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D6866A0-1FED-2171-E053-F662850A490D","latestVersionIndicator":"Yes","beginDate":"2018-12-19","endDate":null,"createdBy":"KEARNSD","dateCreated":"2018-12-19","modifiedBy":"KEARNSD","dateModified":"2019-01-22","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6672767","version":"1","preferredName":"Radiation Therapy Prophylactic Cranial Irradiation Type","preferredDefinition":"Information related to the radiation therapy treatment approach that will be used on the head to reduce the risk that cancer will spread to the brain._Radiation therapy to the head to reduce the risk that cancer will spread to the brain._Something distinguishable as an identifiable class based on common qualities.","longName":"3923093v1.0:6672706v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"83EA06E9-52F3-1690-E053-F662850A3A68","latestVersionIndicator":"Yes","beginDate":"2019-03-12","endDate":null,"createdBy":"NELSONA","dateCreated":"2019-03-12","modifiedBy":"SOKKERL","dateModified":"2019-11-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6682291","version":"1","preferredName":"Image Storage Consent Yes No Indicator","preferredDefinition":"Any record of an imaging event whether physical or electronic._The act of safekeeping goods in a depository._Permission to do something._Any record of an imaging event whether physical or electronic._The act of safekeeping goods in a depository._Permission to do something._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"6682290v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8540DC51-47BB-6DD6-E053-F662850ABDE7","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"SHEARMA","dateCreated":"2019-03-29","modifiedBy":"JOOSTENT","dateModified":"2020-04-23","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6682375","version":"1","preferredName":"Patient International Prognostic Index Total International Prognostic Score","preferredDefinition":"information relating to a patient's International Prognostic Index, which is comprised of five factors that help doctors assess how a non-Hodgkins lymphoma patient might respond to a certain treatment or predict the risk of disease recurrence and survival following therapy; the factors are: 1) patient's age, 2) stage of disease: an indication of how localized or widespread is the disease, 3) LDH levels: serum levels often correlate with the amount of tumor in the body, 4) the number of extranodal, non-lymphatic sites found, 5) the patient's overall health._Pertaining to an entirety or whole, also constituting the full quantity or extent; complete; derived by addition._Concerning or belonging to two or more nations._Having value for making predictions._A number or range of numeric values measuring performance, function, quality, or ability.","longName":"2500205v1.0:6682374v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8541908B-8E98-3401-E053-F662850A279D","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"SHEARMA","dateCreated":"2019-03-29","modifiedBy":"SHEIKHM","dateModified":"2021-03-17","changeNote":"3/28/2017 added alt question text for CTSP task, wz.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6682401","version":"1.1","preferredName":"Assessment Stage IV Method Yes No Indicator","preferredDefinition":"The indication of whether or not a tumor or lesion has been assessed as disease Stage IV.","longName":"3115884v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B82AD9C0-5D80-26DA-E053-4EBD850A0DA1","latestVersionIndicator":"Yes","beginDate":"2019-03-29","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2021-01-05","modifiedBy":"HARTLEYG","dateModified":"2021-01-05","changeNote":"Versioned due to requirement of a human-readable definition_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6770819","version":"1","preferredName":"Prior Vascular Endothelial Growth Factor Antibody Therapy Received CDUS Ind-2 Code","preferredDefinition":"information related to prior receiving of therapy that includes drugs which bind to vascular endothelial growth factor (VEGF) receptors without causing activation, thus blocking the production of new blood vessels and enhanced vessel permeability by the VEGF._the coded yes/no indicator for the Clinical Data Update System reporting/exchange guidelines.","longName":"2974534v1.0:2453201v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"GOG CRF:Gynecologic Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"89FD6059-1D6B-59F7-E053-F662850A6E25","latestVersionIndicator":"Yes","beginDate":"2019-05-28","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2019-05-28","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":"Replaced VD Therapy Ind-2 2018279v1 with VD ID#3506068 - Yes No Indicator - dbw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6813204","version":"1","preferredName":"Patient Questionnaire Language Assessment Language Type","preferredDefinition":"the type of language (e.g., English, Spanish) used in an assessment.","longName":"6813203v1.0:2670708v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCBF291-88ED-7A00-E053-F662850AA02A","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"KEARNSD","dateCreated":"2019-07-03","modifiedBy":"SOKKERL","dateModified":"2023-06-06","changeNote":"Add VDs for more languages - 2/20/20, DH; added VD for \"NA (Pt does not speak or read English or Spanish)","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6816207","version":"1","preferredName":"Demographics Domain Sex Sex Type","preferredDefinition":"A subject domain utilized for the submission of information encompassing and representing data, vocabulary or records related to demographics._The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female._The assemblage of physical properties or qualities by which male is distinguished from female; the physical difference between male and female; the distinguishing peculiarity of male or female._Something distinguishable as an identifiable class based on common qualities.","longName":"6412386v1.0:4184700v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8D6B3A24-0BE8-02AB-E053-F662850AE2A1","latestVersionIndicator":"Yes","beginDate":"2019-07-11","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2019-07-11","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"6974953","version":"1","preferredName":"RET Fusion Positive Lung Non-Small Cell Carcinoma Determine Patient Yes No Indicator","preferredDefinition":"This gene plays an essential role in neural crest development, cellular growth and differentiation. Mutations in the gene are associated with a variety of neoplasias and carcinomas._Confirmation of something, such as a positive lab test. In medicine, a positive lab test indicates the presence of a disease, condition, or microorganism. (NCI)_A group of at least three distinct histological types of lung cancer, including non-small cell squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. Non-small cell lung carcinomas have a poor response to conventional chemotherapy._The establishment of a state or result._Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"6974952v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9481900E-D731-1E48-E053-F662850AE26B","latestVersionIndicator":"Yes","beginDate":"2019-10-09","endDate":null,"createdBy":"NELSONA","dateCreated":"2019-10-09","modifiedBy":"KEARNSD","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7030217","version":"1","preferredName":"Tumor Histologic Stratification Code","preferredDefinition":"The coded response related to tumor histologic stratification analysis.","longName":"2186002v1.0:7030214v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9600B034-8CA6-3211-E053-F662850A759D","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"AUGERG","dateCreated":"2019-10-28","modifiedBy":"SOKKERL","dateModified":"2022-11-10","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7030231","version":"1","preferredName":"Patient Risk Eligibility Determination Recurrent Disease Stratification Code","preferredDefinition":"information relating to the risk assessment criteria to determine eligibility of patients for medical care programs and services._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The return of a disease after a period of remission._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"2963338v1.0:7030222v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9600620D-8EF0-7642-E053-F662850A6F1D","latestVersionIndicator":"Yes","beginDate":"2019-10-28","endDate":null,"createdBy":"AUGERG","dateCreated":"2019-10-28","modifiedBy":"KEARNSD","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7122787","version":"1","preferredName":"Patient Southwest Oncology Group Identifier Patient Identifier Status","preferredDefinition":"information related to the patient's SWOG ID._the status relating to a patient's identifier.","longName":"2195079v1.0:2697198v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9B90F217-9199-1C06-E053-F662850AE5EB","latestVersionIndicator":"Yes","beginDate":"2020-01-07","endDate":null,"createdBy":"AUGERG","dateCreated":"2020-01-07","modifiedBy":"CLOHNES","dateModified":"2022-06-27","changeNote":null,"administrativeNotes":"6/27/22 add AQT for SWOG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7136096","version":"1","preferredName":"Radiation Type Radiation Therapy Type Name","preferredDefinition":"Designation of the type of irradiation used for therapy._Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation._Something distinguishable as an identifiable class based on common qualities._The words or language units by which a thing is known.","longName":"2012436v3.0:7136095v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BCED566-B748-2E99-E053-F662850A5709","latestVersionIndicator":"Yes","beginDate":"2020-01-10","endDate":null,"createdBy":"AUGERG","dateCreated":"2020-01-10","modifiedBy":"KEARNSD","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7165931","version":"1.1","preferredName":"Zubrod Performance Status Stratification Code","preferredDefinition":"information relating to process of classifying patients into strata as part of the randomization process of the action plan for a clinical trial by the Zubrod Performance Status classification._the coded value related to the Zubrod performance status for a patient.","longName":"2200975v1.0:2200977v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9E510C09-1C78-4F0B-E053-F662850A404C","latestVersionIndicator":"Yes","beginDate":"2020-02-11","endDate":null,"createdBy":"AUGERG","dateCreated":"2020-02-11","modifiedBy":"KEARNSD","dateModified":"2021-05-11","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7181399","version":"1","preferredName":"Participant Speak Read Language Specify","preferredDefinition":"The free text field to specify the language spoken and read by a participant.","longName":"7181397v1.0:7181398v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F09565F-7021-2F72-E053-F662850AE9AC","latestVersionIndicator":"Yes","beginDate":"2020-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2020-02-20","modifiedBy":"FINCHAMB","dateModified":"2023-05-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7181407","version":"1","preferredName":"Participant Chronic Lymphocytic Leukemia International Prognostic Index Risk Score Status Stratification Code","preferredDefinition":"The stratification code associated with a participant's CLL-IPI risk score status.","longName":"7181402v1.0:7181404v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F0947A0-C772-2FBA-E053-F662850A54DE","latestVersionIndicator":"Yes","beginDate":"2020-02-20","endDate":null,"createdBy":"KEARNSD","dateCreated":"2020-02-20","modifiedBy":"KEARNSD","dateModified":"2020-08-25","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7197419","version":"1","preferredName":"Patient Risk Recurrent Disease Stratification Code","preferredDefinition":"information relating to the risk assessment criteria to determine eligibility of patients for medical care programs and services._A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary._The return of a disease after a period of remission._The process of classifying patients into a sequence of grades or ranks as part of the randomization process or for purposes of data analysis._The return of a disease after a period of remission._A symbol or combination of symbols which is assigned to the members of a collection.","longName":"2963338v1.0:7197415v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A072C303-977E-4ACF-E053-F662850AB07C","latestVersionIndicator":"Yes","beginDate":"2020-03-10","endDate":null,"createdBy":"AUGERG","dateCreated":"2020-03-10","modifiedBy":"SOKKERL","dateModified":"2022-11-29","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244352","version":"1","preferredName":"Surgical Procedure Pathology Lead Contact Name","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Be in charge of; a position of leadership._of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._a channel for communication between groups_A procedure to remove or repair a part of the body or to find out whether disease is present. An operation._The words or language units by which a thing is known.","longName":"7244347v1.0:5406151v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CC17A6-2743-28DB-E053-F662850AC09E","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2020-04-08","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244357","version":"1","preferredName":"Surgical Procedure Pathology Lead Contact Email","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Be in charge of; a position of leadership._of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._a channel for communication between groups_A procedure to remove or repair a part of the body or to find out whether disease is present. An operation._the electronic mail address for a person or organization.","longName":"7244347v1.0:2018387v4.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CC17A6-2766-28DB-E053-F662850AC09E","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2020-04-08","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7244358","version":"1","preferredName":"Surgical Procedure Pathology Lead Contact Phone Number","preferredDefinition":"The medical science, and specialty practice, concerned with all aspects of disease, but with special reference to the essential nature, causes, and development of abnormal conditions, as well as the structural and functional changes that result from the disease processes. Informally used to mean the result of such an examination._Be in charge of; a position of leadership._of or relating to or involving or used in surgery or requiring or amenable to treatment by surgery._a channel for communication between groups_A procedure to remove or repair a part of the body or to find out whether disease is present. An operation._the telephone number of a person or organization.","longName":"7244347v1.0:2016227v3.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A2CC17A6-2785-28DB-E053-F662850AC09E","latestVersionIndicator":"Yes","beginDate":"2020-04-08","endDate":null,"createdBy":"JOOSTENT","dateCreated":"2020-04-08","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7353190","version":"1","preferredName":"Health Economics Clinical Study Refuse Site Participation Yes No Indicator","preferredDefinition":"Refers to a person's state of physical, mental and social well-being; usually it refers specifically to the state of being in good health, a state of complete physical, mental and social well-being, and does not consist only of the absence of disease or infirmity. In any organism health constitutes a form of homeostasis with inputs and outputs of energy and mass in approximate equilibrium allowing for growth and continued survival. In humans, a subjective feeling of well-being coming from somatic and cognitive perceptions is considered an essential component of health._The branch of social science that deals with the production and distribution and consumption of goods and services and their management._Research conducted with human subjects or on material of human origin in which an investigator directly interacts with human subjects; includes development of new technologies, study of mechanisms of human diseases, therapy, clinical trials, epidemiologic, behavior, and health services research._To decline to do, accept, give, or allow something._Site; position in relation to the surroundings._The act of taking part in an activity._The preferred Value Domain to indicate a question with permissible values of yes/no.","longName":"7353184v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AA930822-5FCE-706B-E053-4EBD850A8BD6","latestVersionIndicator":"Yes","beginDate":"2020-07-16","endDate":null,"createdBy":"NELSONA","dateCreated":"2020-07-16","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7385445","version":"1","preferredName":"Disease Status","preferredDefinition":"The condition or state of disease at a particular time.","longName":"7252510v1.0:7252507v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC8E5030-50A9-0686-E053-4EBD850A485C","latestVersionIndicator":"Yes","beginDate":"2020-08-10","endDate":null,"createdBy":"AUGERG","dateCreated":"2020-08-10","modifiedBy":"KEARNSD","dateModified":"2020-08-26","changeNote":"4-20-20 NSV created for TRC-10446; tmt.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7577008","version":"1","preferredName":"First Identifier Spouse Individuals Name","preferredDefinition":"Preceding all others in time or space or degree._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._A person's partner in marriage._The words or language units by which a thing is known.","longName":"7577003v1.0:2018284v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB13F81D-FE71-10A9-E053-4EBD850A963D","latestVersionIndicator":"Yes","beginDate":"2021-02-11","endDate":null,"createdBy":"NELSONA","dateCreated":"2021-02-11","modifiedBy":"KEARNSD","dateModified":"2021-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7577009","version":"1","preferredName":"Middle Identifier Spouse Individuals Name","preferredDefinition":"An intermediate part or section; an area that is approximately central within some larger region._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._A person's partner in marriage._The words or language units by which a thing is known.","longName":"7577007v1.0:2018284v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB140A0D-7A6F-10B9-E053-4EBD850ACD78","latestVersionIndicator":"Yes","beginDate":"2021-02-11","endDate":null,"createdBy":"NELSONA","dateCreated":"2021-02-11","modifiedBy":"KEARNSD","dateModified":"2021-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7577013","version":"1","preferredName":"Last Identifier Spouse Individuals Name","preferredDefinition":"Coming after all others in time or space or degree or being the only one remaining._One or more characters used to identify, name, or characterize the nature, properties, or contents of a thing._A person's partner in marriage._The words or language units by which a thing is known.","longName":"7577005v1.0:2018284v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BB13CF5D-77B1-10A5-E053-4EBD850A69E2","latestVersionIndicator":"Yes","beginDate":"2021-02-11","endDate":null,"createdBy":"NELSONA","dateCreated":"2021-02-11","modifiedBy":"KEARNSD","dateModified":"2021-02-24","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591719","version":"1","preferredName":"Zubrod Performance Status SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify disease progression and how the disease affects the daily living abilities of the patient.","longName":"ZUBROD_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD0EF3F8-9186-6A84-E053-4EBD850A3166","latestVersionIndicator":"Yes","beginDate":"2021-03-08","endDate":null,"createdBy":"AUGERG","dateCreated":"2021-03-08","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/18/21 Edits to DN CDE; TL. 4/9/21 Edits to Draft New CDE; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591727","version":"1","preferredName":"Laboratory Procedure Estimated Creatinine Clearance SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify the estimated clearance of endogenous creatinine.","longName":"CRTCLRE_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD0F340E-44B4-56B8-E053-4EBD850ADE33","latestVersionIndicator":"Yes","beginDate":"2021-03-08","endDate":null,"createdBy":"AUGERG","dateCreated":"2021-03-08","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/18/21 Edits to DN CDE; TL. 4/9/21 Edits to Draft New CDE; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591763","version":"1","preferredName":"Primary Neoplasm Histologic Classification SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify histology of the primary tumor.","longName":"PRI_NEO_HIST_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD1EB1D0-DCB2-27ED-E053-4EBD850AC469","latestVersionIndicator":"Yes","beginDate":"2021-03-09","endDate":null,"createdBy":"AUGERG","dateCreated":"2021-03-09","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/18/21 Edits to DN CDE; TL. 4/9/21 Edits to Draft New CDE; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7591779","version":"1","preferredName":"Disease or Disorder Planned Management Type","preferredDefinition":"The text description of the planned management for disease.","longName":"7591778v1.0:7591775v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BD1F4434-ED2E-5CA7-E053-4EBD850A1A7D","latestVersionIndicator":"Yes","beginDate":"2021-03-09","endDate":null,"createdBy":"AUGERG","dateCreated":"2021-03-09","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 4/9/21 Edits to Draft New CDE; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7621072","version":"1","preferredName":"Biomarker Profile Approach Type","preferredDefinition":"The kind of approach used for biomarker profiling.","longName":"7621070v1.0:7621059v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BEEFD45C-6F3A-114A-E053-4EBD850AFF83","latestVersionIndicator":"Yes","beginDate":"2021-04-01","endDate":null,"createdBy":"NELSONA","dateCreated":"2021-04-01","modifiedBy":"TAYLORT","dateModified":"2021-05-12","changeNote":"Edits to Draft New CDE per semantics and BRs; TL.  Released per AN; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7626494","version":"1","preferredName":"Person Cigarette Smoking History Indicator","preferredDefinition":"An indication as to whether the person has smoked cigarettes.","longName":"CIGSMOK_HX","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF3F093F-FF77-739C-E053-4EBD850A0E80","latestVersionIndicator":"Yes","beginDate":"2021-04-05","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-05","modifiedBy":"TAYLORT","dateModified":"2021-04-07","changeNote":"TL curated for SWOG registration forms.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7629584","version":"1","preferredName":"Primary Neoplasm Stage SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify the extent of tumor involvement at the primary site.","longName":"TSTAG_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BF8F8665-43CE-72E6-E053-4EBD850A4E0C","latestVersionIndicator":"Yes","beginDate":"2021-04-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-09","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/18/21 Edits to DN CDE; TL. S1934; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7639485","version":"1","preferredName":"Clinical Trial Protocol Planned Chemotherapy Type","preferredDefinition":"The type of planned protocol chemotherapy.","longName":"PROT_PLAND_CHEMO_TYP","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C07F538F-2F17-1F29-E053-4EBD850AD50C","latestVersionIndicator":"Yes","beginDate":"2021-04-21","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-21","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S1934; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7648807","version":"1","preferredName":"Participant Questionnaire Completion Method Code","preferredDefinition":"A character or string that represents the short code for the manner of participant completed questionnaires.","longName":"QS_COMP_METH_CODE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1389AA5-DB37-0B75-E053-4EBD850ABB29","latestVersionIndicator":"Yes","beginDate":"2021-04-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-04-30","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2013; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7653556","version":"1","preferredName":"Neoplasm Origin Anatomic Site Stratification Factor Code","preferredDefinition":"A symbol or combination of symbols used to determine the selected pre-treatment factors by which patients are segregated to assure equal balance of these factors before randomization to the intervention arms of a clinical protocol based on tumor origin location.","longName":"TUM_ORIGN_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C221D36D-D374-176C-E053-4EBD850AFA57","latestVersionIndicator":"Yes","beginDate":"2021-05-12","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-05-12","modifiedBy":"KEARNSD","dateModified":"2021-07-22","changeNote":"TL.; Add new text for PV \"3\" - 7/22/21, DH;","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7681494","version":"1","preferredName":"Disease or Disorder Status Prior To Resection SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify the patient's disease status prior to resection.","longName":"DZ_STAT_PR_RES_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4533816-25DF-7F46-E053-4EBD850AEF39","latestVersionIndicator":"Yes","beginDate":"2021-06-09","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-06-09","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/18/21 Edits to DN CDE; TL. S2104; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7684395","version":"1","preferredName":"Zaidi Recurrence Risk Score SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify the prognostic risk score that stratifies recurrence-free survival for patients with resected pancreatic neuroendocrine tumors.","longName":"RSS_SCORE_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C46CCB9A-E643-5DCA-E053-4EBD850AB49E","latestVersionIndicator":"Yes","beginDate":"2021-06-10","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-06-10","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 6/17/21 Edit to Draft New CDE to change the associated VD. 6/10/21 S2104; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7739479","version":"1","preferredName":"Disease or Disorder Histology Category SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify a person's category of disease histology.","longName":"DZ_HIST_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C71633BC-75E7-3FA6-E053-4EBD850A7E11","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-14","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S1800D; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7739480","version":"1","preferredName":"Protocol Agent Therapeutic Procedure Planned Occurrence Stratification Coded Indicator","preferredDefinition":"The coded response as to whether a person intends to take protocol therapeutic agents as part of the randomization process.","longName":"PROT_AGNT_PLAN_TX_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C716882B-7BB3-53D2-E053-4EBD850A748B","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-14","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S1800D; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7739481","version":"1","preferredName":"Therapeutic Procedure Resistance Process Category SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify a person's category of resistance to therapy.","longName":"TX_RES_PRO_CAT_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7169EC8-9A46-6A61-E053-4EBD850A4999","latestVersionIndicator":"Yes","beginDate":"2021-07-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-07-14","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S1800D; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7767320","version":"1","preferredName":"MRI  PET Or CT Image Study Choose Participation Indicator","preferredDefinition":"A response to indicate if a person chose to participate in a MRI, PET or CT imaging study.","longName":"7767313v1.0:3506068v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9C7E7D5-A781-6D5F-E053-4EBD850A879E","latestVersionIndicator":"Yes","beginDate":"2021-08-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-17","modifiedBy":"KUMMEROA","dateModified":"2021-08-18","changeNote":"2021-8-17 ak Created for SWOG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7767392","version":"1","preferredName":"MRI PET Or CT Image Study Declined to Participate Reason Text","preferredDefinition":"The free text field to specify the reason for declining to participate in a MRI, PET or CT imaging study.","longName":"MRI_PET_CT_IMG_DCLN_PTCP_RESN","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9D4C6B1-E3E6-6807-E053-4EBD850ADB3F","latestVersionIndicator":"Yes","beginDate":"2021-08-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-18","modifiedBy":"KUMMEROA","dateModified":"2021-08-18","changeNote":"2021-8-18 ak Created for SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7768018","version":"1","preferredName":"Sample  And Information Storage Future Use Consent  Indicator","preferredDefinition":"Text term of yes, no or not applicable to signify if consent has been granted to store samples and information from an individual for future use.","longName":"SM_IF_STG_FR_CON_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9E9C17E-3B57-033A-E053-4EBD850A710F","latestVersionIndicator":"Yes","beginDate":"2021-08-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-19","modifiedBy":"KUMMEROA","dateModified":"2021-08-19","changeNote":"2021-8-19 ak Created for SWOG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7768022","version":"1","preferredName":"Collected Blood Sample And Information Storage Future Use Consent Indicator","preferredDefinition":"Text term of yes, no or not applicable to signify if consent has been granted to store blood samples and information from an individual for future use.","longName":"BS_IF_SRG_FTR_CN_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EA7D32-1028-7B69-E053-4EBD850AF28D","latestVersionIndicator":"Yes","beginDate":"2021-08-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-19","modifiedBy":"KUMMEROA","dateModified":"2021-08-19","changeNote":"2021-8-19 ak Created for SWOG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7768026","version":"1","preferredName":"Collected Stool Sample And Information Storage Future Use Consent  Indicator","preferredDefinition":"Text term of yes, no or not applicable to signify if consent has been granted to store stool samples and information from an individual for future use.","longName":"FS_IF_SRG_FTR_CN_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C9EA7D32-1049-7B69-E053-4EBD850AF28D","latestVersionIndicator":"Yes","beginDate":"2021-08-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2021-08-19","modifiedBy":"GDEEN","dateModified":"2023-02-21","changeNote":"2021-8-19 ak Created for SWOG.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7798210","version":"1","preferredName":"Prior Systemic Line of Therapy Count SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system for stratifying the number of prior lines of systemic therapy.","longName":"7798209v1.0:7691683v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE578AC2-C98F-79FD-E053-4EBD850A11E9","latestVersionIndicator":"Yes","beginDate":"2021-10-14","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-10-14","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2107; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7798397","version":"1","preferredName":"Patient Performance Status Assessment SWOG Stratification Code","preferredDefinition":"The Southwest Oncology Group coding system to stratify performance status.","longName":"3288345v1.0:7691683v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CE662E3E-9CC7-368C-E053-4EBD850AADB4","latestVersionIndicator":"Yes","beginDate":"2021-10-15","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-10-15","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"12/9/21 TL released AI. S2107; TL.","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801098","version":"1","preferredName":"Patient Current AJCC Melanoma Staging Clinical Trial Eligibility Criteria Code","preferredDefinition":"The code that represents the patient's current AJCC melanoma staging as outlined in the eligibility criteria of the protocol.","longName":"STAGING","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5C6728-AACB-4723-E053-4EBD850A8F85","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Enrollment Question.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801110","version":"1","preferredName":"Patient Cutaneous Melanoma Breslow Thickness Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation for questions relating to the diagnosis of cutaneous melanoma with breslow thickness as outlined in the study protocol.","longName":"BRESLOW","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF5CE68C-966B-16DB-E053-4EBD850ABC8E","latestVersionIndicator":"Yes","beginDate":"2021-10-27","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-27","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801141","version":"1","preferredName":"Patient AJCC Cancer Staging Manual 8th Edition Melanoma T Category Clinical Trial Eligibility Criteria Staging Code","preferredDefinition":"The code that represents the patient's T stage for melanoma according to the American Joint Committee on Cancer Staging Manual, Edition 8, as outlined in the eligibility criteria of the protocol","longName":"HISTREPORTSTAGEDISPLAY","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6B883E-BB01-21FE-E053-4EBD850A2AF8","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Enrollment Question","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801231","version":"1","preferredName":"White Light Endoscopy Sentinel Lymph Node Biopsy Planned Date","preferredDefinition":"The date of the planned white light endoscopy/sentinel lymph node biopsy.","longName":"PLANNEDSLNBDATE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CF6DB4B0-D2B4-1146-E053-4EBD850A788A","latestVersionIndicator":"Yes","beginDate":"2021-10-28","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-10-28","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. 10/28/21 ls","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801511","version":"1","preferredName":"Patient Primary Cutaneous Melanoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to a primary melanoma.","longName":"CUTANEOUS","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBB55BF-B206-3A24-E053-4EBD850AB13E","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801520","version":"1","preferredName":"Patient Informed Consent And Compliance Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to informed consent and compliance to the protocol requirements.","longName":"ABLEINFORMEDCONSENT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBB55BF-B227-3A24-E053-4EBD850AB13E","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Enrollment.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801526","version":"1","preferredName":"Sentinel Lymph Node Biopsy Staging Complete Timepoint Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for clinical trial participation with regards to the timepoint of completion for a staging sentinel node biopsy.","longName":"COMPLETEWITHIN120DAYS","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBCA747-8B34-1BC5-E053-4EBD850AD318","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"KEARNSD","dateModified":"2022-01-25","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801528","version":"1","preferredName":"Patient Age Eligibility Determination Code Indicator","preferredDefinition":"The coded response as to whether the patient's age meets the eligibility criteria for participating in a clinical trial.","longName":"AGE18","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBCA747-8B55-1BC5-E053-4EBD850AD318","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801532","version":"1","preferredName":"Patient Life Expectancy Eligibility Determination Code Indicator","preferredDefinition":"The coded response as to whether the patient has a life expectancy that meets the eligibility requirements for participation in the clinical trial.","longName":"LIFE5","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBD5036-9042-2EE0-E053-4EBD850A4AF8","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801535","version":"1","preferredName":"Eastern Cooperative Oncology Group Performance Status Assessment Code","preferredDefinition":"The coded response for ECOG Performance Status.","longName":"ECOG","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBDA9D8-2E03-27EF-E053-4EBD850AF7E8","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801536","version":"1","preferredName":"Eastern Cooperative Oncology Group Performance Status Assessment Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to an ECOG performance score.","longName":"ECOG01","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFBDB567-E989-32C2-E053-4EBD850A60FA","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801574","version":"1","preferredName":"Patient Prior Cancer Survivor Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient, who is a survivor of prior cancer, meets the eligibility criteria for clinical trial participation.","longName":"SURVIVOR","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC408B5-8B41-3EF6-E053-4EBD850ADA99","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"KEARNSD","dateModified":"2022-01-20","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801578","version":"1","preferredName":"Patient Uncertain Melanoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to an uncertain diagnosis of melanoma.","longName":"UNCERTAIN","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC408B5-8B62-3EF6-E053-4EBD850ADA99","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801582","version":"1","preferredName":"Patient Primary Index Lesion Wide Local Excision Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to a wide local excision of the primary index lesion.","longName":"WLE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC44EFC-E00C-0ACD-E053-4EBD850A20A8","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801586","version":"1","preferredName":"Patient Primary Index Lesion Sentinel Lymph Node Biopsy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for clinical trial participation with regards to a staging sentinel lymph node biopsy of the primary index lesion.","longName":"UNABLESLNB","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC46A42-B772-44C5-E053-4EBD850AFCCB","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801587","version":"1","preferredName":"Patient Melanoma Diagnosis Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient's diagnosis of melanoma meets the eligibility criteria for clinical trial participation.","longName":"DESMOPLASTIC","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC381D8-59D3-426E-E053-4EBD850AA93F","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801591","version":"1","preferredName":"Patient Microsatellitosis AJCC Cancer Staging Manual 8th Edition Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to microsatellitosis as defined by the AJCC Cancer Staging Manual 8th Edition.","longName":"MICROSAT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC4D636-A9FE-6899-E053-4EBD850ADABA","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801595","version":"1","preferredName":"Patient Subungual Melanoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to subungual melanoma.","longName":"SUBUNGUAL","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC0C1D3-0265-0261-E053-4EBD850AD281","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801599","version":"1","preferredName":"Patient Local Flap Surgical Reconstruction Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to a local flap reconstruction.","longName":"RECONSTRUCT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC361EE-A8F8-4E21-E053-4EBD850A6C38","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801600","version":"1","preferredName":"Patient Personal Medical History Invasive Cutaneous Melanoma Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient's medical history of invasive melanoma meets the eligibility criteria for participating in a clinical trial.","longName":"MELINV","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFC5245C-BA20-3927-E053-4EBD850A677E","latestVersionIndicator":"Yes","beginDate":"2021-11-01","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-01","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801617","version":"1","preferredName":"Patient Melanoma Anatomic Site Location Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to the anatomic location of melanoma.","longName":"LOWMARGIN","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCC9163-A67D-0D24-E053-4EBD850A28AA","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801621","version":"1","preferredName":"Patient Metastatic Melanoma Evidence Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"A coded indicator to determine clinical trial participation for questions addressing evidence of metastatic melanoma as outlined in the study protocol.","longName":"DMM","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCC9163-A6CB-0D24-E053-4EBD850A28AA","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801625","version":"1","preferredName":"Patient Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient's surgery meets the eligibility criteria for participating in a clinical trial.","longName":"SURGLYMPH","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD004D-BF9B-0D1E-E053-4EBD850AF0A2","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801629","version":"1","preferredName":"Patient Additional Neoplasm Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to additional benign or malignant tissue growth resulting from uncontrolled cell proliferation.","longName":"SQUAMOUS","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCC9EAB-FA9A-0D15-E053-4EBD850AD3BE","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801633","version":"1","preferredName":"Patient Melanoma Related Surgical Procedure Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to melanoma-related operative procedures.","longName":"MELOPREL","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD004D-BFBA-0D1E-E053-4EBD850AF0A2","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801637","version":"1","preferredName":"Patient Primary Neoplasm Adjuvant Radiation Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for clinical trial participation with regards to adjuvant radiation therapy to the primary neoplasm.","longName":"RADPRIMWLE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD0B43-19E0-38D7-E053-4EBD850A793A","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801638","version":"1","preferredName":"Patient Personal Medical History Organ Transplantation Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient's medical history an organ transplant meets the eligibility criteria for participating in a clinical trial.","longName":"ORGANTRANS","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD4D5F-65AD-38D4-E053-4EBD850AC397","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801639","version":"1","preferredName":"Patient Immunosuppressive Therapy Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to immunosuppressive agents.","longName":"ORALAGENT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD004D-BFE2-0D1E-E053-4EBD850AF0A2","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"KEARNSD","dateModified":"2022-01-25","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801644","version":"1","preferredName":"Patient Gender Code","preferredDefinition":"The coded response for patient gender.","longName":"GENDER","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCD004D-C003-0D1E-E053-4EBD850AF0A2","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801655","version":"1","preferredName":"Patient Age Randomization Code","preferredDefinition":"The coded response for the patient's age at randomization.","longName":"AGEBRACKET","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCDAF84-8CD7-03F5-E053-4EBD850ABE1A","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801664","version":"1","preferredName":"Country Name Code","preferredDefinition":"The coded response for the name of a country.","longName":"COUNTRY","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCDE12F-2558-0212-E053-4EBD850ACD56","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801672","version":"1","preferredName":"Withdrawal by Subject Reason Code","preferredDefinition":"The coded response to address the reason for the patient's withdrawal from the study.","longName":"WITHDRAWAL","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCE1BD9-4CDC-6141-E053-4EBD850A94CD","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801690","version":"1","preferredName":"Patient Trial Screen Failure Reason Code","preferredDefinition":"The coded response to address the reason for screen failure.","longName":"SCREENFAIL","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCE87E9-D846-73E3-E053-4EBD850A3A7C","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801722","version":"1","preferredName":"Patient Uninterrupted Margin Clinical Trial Eligibility Criteria Code Indicator","preferredDefinition":"The coded response as to whether the patient meets the eligibility criteria for participating in a clinical trial with regards to uniform margins.","longName":"2CMMARGIN","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCE80E3-065E-012C-E053-4EBD850A0AFF","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2015 Enrollment Question","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7801759","version":"1","preferredName":"Patient Trial Screen Failure Eligibility Criteria Number","preferredDefinition":"The number that corresponds to the eligibility criteria required for participation in a trial that the potential subject failed to meet.","longName":"CRITERION","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFCFCACC-E02D-0FC0-E053-4EBD850AE74A","latestVersionIndicator":"Yes","beginDate":"2021-11-02","endDate":null,"createdBy":"SOKKERL","dateCreated":"2021-11-02","modifiedBy":"KEARNSD","dateModified":"2022-01-25","changeNote":"12/9/21 TL released AI. S2015 Eligibility.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"7843527","version":"1","preferredName":"Prior Chemotherapy Regimen Code","preferredDefinition":"A symbol or combination of symbols which is assigned to the prior regimen of chemotherapy.","longName":"CHEMO_CODE","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D17BEFFF-CD6F-43FD-E053-4EBD850A3F85","latestVersionIndicator":"Yes","beginDate":"2021-11-23","endDate":null,"createdBy":"TAYLORT","dateCreated":"2021-11-23","modifiedBy":"TAYLORT","dateModified":"2021-12-09","changeNote":"12/9/21 TL released AI. S2001; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8014343","version":"1","preferredName":"Participant Registration Randomization Eligibility Determination Numeric Indicator Code","preferredDefinition":"A coded numeric response as to whether the patient is eligible for randomization.","longName":"3243016v1.0:2222697v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67DCD28-25CA-4053-E053-4EBD850ADA3E","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-26","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeNote":"TL released; 2/24/22. S2015; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8014362","version":"1","preferredName":"Patient Negation Randomization Reason Code","preferredDefinition":"A coded numeric response for why the patient will not be randomized.","longName":"8014359v1.0:8014360v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D67E2AFB-D14E-6255-E053-4EBD850A24FF","latestVersionIndicator":"Yes","beginDate":"2022-01-26","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-01-26","modifiedBy":"TAYLORT","dateModified":"2022-02-24","changeNote":"TL released; 2/24/22. S2015; tl.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8072475","version":"1","preferredName":"Patient Neoplasm Sarcomatoid Features Stratification Factors Coded Indicator","preferredDefinition":"A numeric coded response for the stratification factor to address the presence of sarcomatoid.","longName":"SARCD_FEATR_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9B87A9C-3736-56FA-E053-4EBD850A5086","latestVersionIndicator":"Yes","beginDate":"2022-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-08","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"S2200 CDE curation; TL.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8072479","version":"1","preferredName":"Patient Systemic Therapy Occurrence Stratification Factors Coded Indicator","preferredDefinition":"A numeric coded response for the stratification factor to address the instance of systemic treatment.","longName":"SYS_TX_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9B87A9C-379E-56FA-E053-4EBD850A5086","latestVersionIndicator":"Yes","beginDate":"2022-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-08","modifiedBy":"CLOHNES","dateModified":"2023-11-22","changeNote":"S2200 CDE curation; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8072486","version":"1","preferredName":"Patient International Metastatic Renal Cell Carcinoma Database Consortium Criteria Risk Score Stratification Factors Code","preferredDefinition":"A numeric coded response for the stratification factor to address the patient's International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Criteria risk score.","longName":"IMDC_RISK_SCOR_STRAT_CD","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D9B92C34-679B-4B8B-E053-4EBD850A4E6D","latestVersionIndicator":"Yes","beginDate":"2022-03-08","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-08","modifiedBy":"TAYLORT","dateModified":"2022-04-18","changeNote":"S2200 CDE curation; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8093117","version":"1","preferredName":"Patient English French Language Eligibility Determination Assessment Indicator","preferredDefinition":"Indication as to whether the patient is suitable for enrollment in a study according to the English and French language protocol criteria.","longName":"ENG_FRN_LGN_DET_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA6E3009-9E8C-3105-E053-4EBD850AF234","latestVersionIndicator":"Yes","beginDate":"2022-03-17","endDate":"2023-05-31","createdBy":"SOKKERL","dateCreated":"2022-03-17","modifiedBy":"GDEEN","dateModified":"2023-05-31","changeNote":null,"administrativeNotes":"05.31.23_Released during Q1 2023 Cleanup b/c CDE has been used on forms","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8093847","version":"1","preferredName":"Patient Questionnaire Language Type","preferredDefinition":"The type of language used for patient questionnaires.","longName":"QS_LANG_TP","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DA7CD6B7-EBAC-4BDF-E053-4EBD850A45CF","latestVersionIndicator":"Yes","beginDate":"2022-03-18","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-03-18","modifiedBy":"KUMMEROA","dateModified":"2024-01-25","changeNote":"TL/SWOG.","administrativeNotes":"2024.1.25 AQT/Alt SN added per ticket request CADSR0003328. ak","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8172947","version":"1","preferredName":"Post Induction Clinical Trial Protocol Therapeutic Procedure Planned Occurrence Type","preferredDefinition":"A response for the type of planned post-induction protocol therapy.","longName":"8172945v1.0:8172946v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD01006C-05DD-3CF2-E053-4EBD850AC5AB","latestVersionIndicator":"Yes","beginDate":"2022-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-19","modifiedBy":"FINCHAMB","dateModified":"2022-09-21","changeNote":"MM1YA-S01; TL","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"8172953","version":"1","preferredName":"Patient TP53 Mutation Analysis Status Stratification Factors Code","preferredDefinition":"A numeric coded response for the stratification factor to address the status of mutations in the TP53 gene.","longName":"8172950v1.0:8172952v1.0","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD037D42-B304-2303-E053-4EBD850AC4AB","latestVersionIndicator":"Yes","beginDate":"2022-04-19","endDate":null,"createdBy":"TAYLORT","dateCreated":"2022-04-19","modifiedBy":"ZHWENDY","dateModified":"2022-07-19","changeNote":"MM1YA-S01; TL","administrativeNotes":"7/19/2022: fixed the box symbol in PQT.wz","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10533495","version":"1","preferredName":"Professional Practice Study Chair Approval Submission Indicator","preferredDefinition":"Has the practice submitted and received approval from the study chair?","longName":"PR_PR_ST_CR_AP_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26FF5FD-8F2B-66FB-E053-731AD00AB816","latestVersionIndicator":"Yes","beginDate":"2022-06-27","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-06-27","modifiedBy":"CLOHNES","dateModified":"2022-06-29","changeNote":null,"administrativeNotes":"6/29/22 released CDE for SWOG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10533503","version":"1","preferredName":"Genomic Tumor Board Review Case Urgency Category","preferredDefinition":"Text term that represents the genomic tumor board review case urgency category.","longName":"GN_TM_BD_RV_CS_UR_CT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26FF5FD-8F4C-66FB-E053-731AD00AB816","latestVersionIndicator":"Yes","beginDate":"2022-06-27","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-06-27","modifiedBy":"CLOHNES","dateModified":"2022-06-29","changeNote":null,"administrativeNotes":"6/29/22 Released CDE for SWOG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10533519","version":"1","preferredName":"Professional Practice Participant Name","preferredDefinition":"Text term used to represent the name of the participating professional practice.","longName":"PRF_PRC_PRT_NM","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E26DC616-2B37-67B5-E053-731AD00AD545","latestVersionIndicator":"Yes","beginDate":"2022-06-27","endDate":null,"createdBy":"CLOHNES","dateCreated":"2022-06-27","modifiedBy":"CLOHNES","dateModified":"2022-06-29","changeNote":null,"administrativeNotes":"6/29/22 Released CDE for SWOG cjl;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10874285","version":"1","preferredName":"Myeloma Frailty Index Status","preferredDefinition":"The response of an individual's frailty as assessed by the Myeloma Frailty Index.","longName":"MYL_FRA_IDX_STAT","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E534BA88-9F3A-461B-E053-731AD00ACEA8","latestVersionIndicator":"Yes","beginDate":"2022-08-01","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-08-01","modifiedBy":"GDEEN","dateModified":"2022-08-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10923307","version":"1","preferredName":"Cytogenetic Abnormality Detection Fluorescence in Situ Hybridization Method Yes No Coded Indicator","preferredDefinition":"The coded response that indicates whether or not cytogenetic abnormalities were detected via fluorescence in situ hybridization.","longName":"CYT_ABN_FISH_CD_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5470A4B-7DA3-0E50-E053-731AD00AC554","latestVersionIndicator":"Yes","beginDate":"2022-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-08-02","modifiedBy":"FINCHAMB","dateModified":"2022-12-09","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"10923309","version":"1","preferredName":"Prior Systemic Therapy Plasma Cell Myeloma Administered Yes No Coded Indicator","preferredDefinition":"The coded response that indicates whether prior plasma cell myeloma systemic therapy was administered.","longName":"PR_SYS_TPY_MYEL_CD_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E54717C1-DF7A-0FE0-E053-731AD00AE391","latestVersionIndicator":"Yes","beginDate":"2022-08-02","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-08-02","modifiedBy":"GDEEN","dateModified":"2022-08-02","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11159081","version":"1","preferredName":"Participant Brain Metastases Coded Indicator","preferredDefinition":"A coded response to indicate whether a participant has a malignant neoplasm that has spread to the brain from another anatomic site or system.","longName":"11159080v1.00:2183836v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E76247C3-562A-33B8-E053-731AD00A98EC","latestVersionIndicator":"Yes","beginDate":"2022-08-29","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-08-29","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"8/29/2022 Created for Greg Auger (SWOG) . BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11167464","version":"1","preferredName":"Prior Therapy Administered Count Code","preferredDefinition":"A coded response to indicate the count of prior lines of therapy administered.","longName":"2197794v1.00:11167463v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E78CB553-C02F-6A5D-E053-731AD00AC9C7","latestVersionIndicator":"Yes","beginDate":"2022-08-31","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-08-31","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11346884","version":"1","preferredName":"Lung Non-Small Cell Carcinoma Most Recent Line of Therapy PD1 Inhibitor PD-1 Ligand Inhibitor Include Yes No Coded Indicator","preferredDefinition":"The response indicating whether or not the most recently NSCLC line of therapy included PD-1 inhibitors or PD-1 ligand inhibitors.","longName":"NSCLC_PD1_PDL1_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EEAE8D-F8A0-7C88-E053-731AD00A5BB2","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-10-03","changeNote":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"11346885","version":"1","preferredName":"Participant Randomization Protocol Treatment Arm Investigator Best Practice Ramucirumab Intent To Treat Yes No Indicator","preferredDefinition":"The response indicating whether the participant will include Ramucirumab as part of their care if randomized to Arm A, the Investigator's Choice of Standard of Care?","longName":"RDZ_ARMA_BSPRCT_IND","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9EEC367-249D-7EEF-E053-731AD00AC336","latestVersionIndicator":"Yes","beginDate":"2022-09-30","endDate":null,"createdBy":"GDEEN","dateCreated":"2022-09-30","modifiedBy":"GDEEN","dateModified":"2022-11-07","changeNote":null,"administrativeNotes":"10.03.22_Curated to support protocol S2302_ghd","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12057523","version":"1","preferredName":"Patient Age Code","preferredDefinition":"The code that represents a patients age","longName":"2185959v1.00:3081823v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED899403-51C0-730E-E053-731AD00A4154","latestVersionIndicator":"Yes","beginDate":"2022-11-15","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-11-15","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"11/15/22 created for SWOG S2010 BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12060148","version":"1","preferredName":"Agent Planned Frequency","preferredDefinition":"The planned frequency of how often a medication is being administered.","longName":"12060147v1.00:2017195v4.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED985B8D-10B8-04F2-E053-731AD00A99FB","latestVersionIndicator":"Yes","beginDate":"2022-11-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-11-16","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12060149","version":"1","preferredName":"Hormone Therapy Planned Agent Dose","preferredDefinition":"The planned hormone therapy dose to be administered.","longName":"2553528v1.00:6245378v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ED98792A-27DA-1857-E053-731AD00A06B5","latestVersionIndicator":"Yes","beginDate":"2022-11-16","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-11-16","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12100414","version":"1","preferredName":"Prior Chemotherapy Administered Coded Indicator","preferredDefinition":"The coded indicator to determine whether prior chemotherapy was administered.","longName":"2188711v1.00:2183836v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC1E0D5-D6BB-77EE-E053-731AD00A8909","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"SOKKERL","dateCreated":"2022-11-18","modifiedBy":"SOKKERL","dateModified":"2023-09-30","changeNote":null,"administrativeNotes":"9/30/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12100431","version":"1","preferredName":"Hormone Therapy Planned Category Code","preferredDefinition":"The code that represents the name of the agent used in the planned treatment modalities that produce the desired therapeutic effect by means of change of hormone/hormones level.","longName":"2553528v1.00:12100422v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"EDC267D0-9835-117D-E053-731AD00A1552","latestVersionIndicator":"Yes","beginDate":"2022-11-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2022-11-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12390765","version":"1","preferredName":"Participant Immune Checkpoint Inhibitor Dose Received Type","preferredDefinition":"The Immune Checkpoint Inhibitor dose (ICI) type the participant will receive.","longName":"12387699v1.00:12387700v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F28C85CC-F263-0BD7-E053-731AD00AF2FA","latestVersionIndicator":"Yes","beginDate":"2023-01-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"1/18/23 Created for SWOG S2013 BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12430795","version":"1","preferredName":"Clinical Trial Protocol Planned Chemotherapy Regimen or Agent Combination Type","preferredDefinition":"A response used to indicate the planned chemotherapy treatment regimen for the participant.","longName":"7639463v1.00:12430772v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2F27178-AC4C-54A3-E053-731AD00A2B3F","latestVersionIndicator":"Yes","beginDate":"2023-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-01-23","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"1/23/23 Created for SWOG. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"12566449","version":"1","preferredName":"Diffuse Large B-Cell Lymphoma Origin Cell Name Code","preferredDefinition":"A coded response to indicate the origin of diffuse large B-cell lymphomas.","longName":"12564979v1.00:12564956v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F4B0723B-303F-0BDC-E053-731AD00A4B3D","latestVersionIndicator":"Yes","beginDate":"2023-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-02-14","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"2/14/23 Created for SWOG S2207. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13110936","version":"1","preferredName":"Non-Small Cell Lung Carcinoma EGFR Activating Mutation Yes No Indicator","preferredDefinition":"A yes/no response for questions addressing EGFR activating mutations with regards to NSCLC.","longName":"5026329v1.00:3506068v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F67B904D-CC0B-66DF-E053-731AD00AE257","latestVersionIndicator":"Yes","beginDate":"2023-03-09","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-03-09","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":"9/30/15 released/tt_9/28/15- 9910_tt.","administrativeNotes":"3/9/23 Curated for SWOG, existing CDE did not meet required PV criteria. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13341064","version":"1","preferredName":"Treating Investigator Treatment of Choice Code","preferredDefinition":"A coded response to indicate the best treatment as determined by the study investigator.","longName":"13341000v1.00:13341021v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F913FA04-3C27-382D-E053-731AD00A4852","latestVersionIndicator":"Yes","beginDate":"2023-04-11","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-04-11","modifiedBy":"SOKKERL","dateModified":"2023-06-20","changeNote":null,"administrativeNotes":"4/11/23 Curated for SWOG (S2207). BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13382776","version":"1","preferredName":"Patient Androgen Suppression Personal Medical History Yes No Coded Indicator","preferredDefinition":"The coded response indicating whether a participant has received prior androgen deprivation therapy.","longName":"2604829v1.00:2183836v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9AB0A-7B7A-2848-E053-731AD00A50DC","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13382781","version":"1","preferredName":"BRCA Gene Mutation Stratification Factors Code","preferredDefinition":"Coded response representing the protocol stratification factors of individuals with a mutation in the nucleotide sequence of BRCA1 or BRCA2 genes.","longName":"3289550v1.00:13382778v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9B9EB36-F30F-3991-E053-731AD00A02BA","latestVersionIndicator":"Yes","beginDate":"2023-04-19","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-04-19","modifiedBy":"GDEEN","dateModified":"2023-09-05","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13535095","version":"1","preferredName":"Nodal Stratification Status","preferredDefinition":"The response indicating the state of disease presence in lymph nodes.","longName":"5126873v1.00:13535094v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FB38314B-CADB-432C-E053-731AD00AC9A4","latestVersionIndicator":"Yes","beginDate":"2023-05-08","endDate":null,"createdBy":"GDEEN","dateCreated":"2023-05-08","modifiedBy":"GDEEN","dateModified":"2023-07-07","changeNote":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13809388","version":"1","preferredName":"Clinical Study Protocol Chemotherapy Neoadjuvant Therapy  Stratification Code","preferredDefinition":"A stratification code to indicate whether neoadjuvant chemotherapy will be administered as outlined in the study protocol.","longName":"3153599v1.00:13809384v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FD787159-ACEA-58AA-E053-731AD00A3DCF","latestVersionIndicator":"Yes","beginDate":"2023-06-06","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-06","modifiedBy":"SOKKERL","dateModified":"2023-09-30","changeNote":null,"administrativeNotes":"9/30/23: Released  melanoma  AI per 3Q23 metric report review. LS","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13966075","version":"1","preferredName":"Central Nervous System Status Stratification Code","preferredDefinition":"A coded response related to the participants sequence of grades or ranks as part of the randomization process or for purposes of data analysis addressing the status of the Central Nervous System.","longName":"2014685v1.00:13966072v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEA986E1-1044-766E-E053-731AD00AB386","latestVersionIndicator":"Yes","beginDate":"2023-06-21","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-21","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"6/21/23 created for SWOG stratification questions. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"13970892","version":"1","preferredName":"Bispecific Monoclonal Antibody Administered Coded Indicator","preferredDefinition":"The yes/no coded response that determines whether or not a participant has received a bispecific monoclonal antibody.","longName":"5095207v1.00:2183836v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBDDC28-D17C-09A4-E053-731AD00A6DA3","latestVersionIndicator":"Yes","beginDate":"2023-06-22","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-06-22","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"6/22/23 created for SWOG stratification questions. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14263650","version":"1","preferredName":"MET Exon 14 Skipping Mutation Positive Lung Non-Small Cell Carcinoma Present Indicator","preferredDefinition":"The response indicating the presence of MET Exon 14 skipping-positive NSCLC that meets the eligibility requirements for participation in a clinical trial and/or study protocol.","longName":"14263649v1.00:3506068v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0206761D-17E9-4504-E063-731AD00AD1C4","latestVersionIndicator":"Yes","beginDate":"2023-08-03","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-08-03","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"8/3/23 created for SWOG. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14427242","version":"1","preferredName":"Mayo Staging System for AL Amyloidosis Initial Study Registration Stage","preferredDefinition":"A coded response that determines the stage at initial study registration as per the Mayo Staging System for AL Amyloidosis.","longName":"14427237v1.00:14427239v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03341D43-37B8-0200-E063-731AD00AC46C","latestVersionIndicator":"Yes","beginDate":"2023-08-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-08-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"8/18/23 Created for SWOG stratification questions.  BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14428013","version":"1","preferredName":"Chemotherapy Hematologic Response Status","preferredDefinition":"The coded response that determines the hematological response following a chemotherapy regimen.","longName":"14427245v1.00:14427614v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"03355AB4-FA88-3A33-E063-731AD00A82B4","latestVersionIndicator":"Yes","beginDate":"2023-08-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-08-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"8/18/23 Created for SWOG stratification questions. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14428018","version":"1","preferredName":"Cytogenetic Abnormality Initial Study Registration Indicator","preferredDefinition":"The coded response that indicates whether or not there was a cytogenic abnormality present at the time of the initial study registration.","longName":"14428014v1.00:14428016v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0335A8BC-D332-4686-E063-731AD00A1115","latestVersionIndicator":"Yes","beginDate":"2023-08-18","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-08-18","modifiedBy":"FINCHAMB","dateModified":"2023-11-01","changeNote":null,"administrativeNotes":"8/18/23 Created for SWOG stratification questions. BF;","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14650256","version":"1","preferredName":"Participant Cohort Type Code","preferredDefinition":"The coded response that identifies the information in which subsets of a defined population are identified for a particular study.","longName":"14650229v1.00:14650239v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0BF1A720-3676-6590-E063-731AD00AC4C1","latestVersionIndicator":"Yes","beginDate":"2023-12-07","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-12-07","modifiedBy":"FINCHAMB","dateModified":"2023-12-13","changeNote":null,"administrativeNotes":"12/7/23 Created for SWOG stratification questions.  BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14651992","version":"1","preferredName":"Person Body Mass Index Value Code","preferredDefinition":"A coded response that represents the calculated weight to height ratio of the participant.","longName":"2014287v1.00:14651989v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C00AF96-F971-7A4A-E063-731AD00AE2CD","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-12-08","modifiedBy":"FINCHAMB","dateModified":"2023-12-19","changeNote":null,"administrativeNotes":"12/8/23 Created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14652036","version":"1","preferredName":"Participant Immunophenotype Category Code","preferredDefinition":"The coded response that answers the question in regards to the participant's immunophenotype category.","longName":"14651995v1.00:14651998v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C01F177-3614-3934-E063-731AD00AC2D0","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-12-08","modifiedBy":"FINCHAMB","dateModified":"2023-12-19","changeNote":null,"administrativeNotes":"12/8/23 Created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14652267","version":"1","preferredName":"Person Age Range Category Code","preferredDefinition":"A coded response that answers questions in regards to a participant's age.","longName":"2634443v1.00:14652058v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0C03035C-8745-797F-E063-731AD00A0BFC","latestVersionIndicator":"Yes","beginDate":"2023-12-08","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2023-12-08","modifiedBy":"FINCHAMB","dateModified":"2023-12-19","changeNote":null,"administrativeNotes":"12/8/23 Created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14672778","version":"1","preferredName":"Participant Follicular Lymphoma International Prognostic Index Score Code","preferredDefinition":"The coded response that answers questions relating to a score as determined by the Participant Follicular Lymphoma International Prognostic Index.","longName":"14672728v1.00:14672730v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E220D3F-A770-37CC-E063-731AD00AE74D","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-04","modifiedBy":"FINCHAMB","dateModified":"2024-01-22","changeNote":null,"administrativeNotes":"1/4/24 created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14672861","version":"1","preferredName":"Prior RT Administered Yes/No Coded Indicator","preferredDefinition":"The yes/no coded indicator that answers the question as to whether the patient had prior radiation therapy.","longName":"2188727v1.00:2183836v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E229486-5C0C-53C5-E063-731AD00A2E5B","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-04","modifiedBy":"FINCHAMB","dateModified":"2024-01-22","changeNote":null,"administrativeNotes":"1/4/24 created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14672868","version":"1","preferredName":"Person Age Code","preferredDefinition":"The coded response that answers questions related to a persons age.","longName":"2634443v1.00:14672865v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E22FDA3-D219-68FD-E063-731AD00A0AA3","latestVersionIndicator":"Yes","beginDate":"2024-01-04","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-04","modifiedBy":"FINCHAMB","dateModified":"2024-01-22","changeNote":null,"administrativeNotes":"1/4/24 created for SWOG stratification questions. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14719364","version":"1","preferredName":"Chemotherapy Agent Name","preferredDefinition":"The coded response used to indicate the name of the drug/agent that is being used for chemotherapy treatment..","longName":"2783412v1.00:14718773v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0FA1DE6E-C22E-558F-E063-731AD00A5CB0","latestVersionIndicator":"Yes","beginDate":"2024-01-23","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-01-23","modifiedBy":"FINCHAMB","dateModified":"2024-02-23","changeNote":null,"administrativeNotes":"1/23/24 Created for SWOG. Previous CDE was retired and new PV's needed to be added. BF","unresolvedIssues":null,"deletedIndicator":"No"},{"publicId":"14758507","version":"1","preferredName":"Person Refractory Disease Prior Therapy Stratification Indicator Code","preferredDefinition":"A coded response to questions related to refractory disease from prior treatment.","longName":"3919194v1.00:3025013v1.00","contextName":"SWOG","contextVersion":"1","dataElementConceptPublicId":"2010953","dataElementConceptVersion":"3","valueDomainPublicId":"2861221","valueDomainVersion":"1.1","origin":"SWOG CRF:Southwest Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"115A7AC9-D6A8-01BA-E063-731AD00A04C7","latestVersionIndicator":"Yes","beginDate":"2024-02-14","endDate":null,"createdBy":"FINCHAMB","dateCreated":"2024-02-14","modifiedBy":"FINCHAMB","dateModified":"2024-02-23","changeNote":null,"administrativeNotes":"2/14/24 Created for SWOG stratification questions.  Duplicate of old CDE 12564954 that had a retired VD. BF","unresolvedIssues":null,"deletedIndicator":"No"}]}